Nvidia (NVDA +2.12%) and Advanced Micro Devices (AMD -0.34%) have been some of the top-performing artificial intelligence (AI) stocks due to their chips, but the next winner may be in networking. Data centers require a significant amount of networking cables, and that can position Arista Networks (ANET -0.22%) to outperform both chipmakers during the next year. Here's what makes the stock worth watching.
Image source: Getty Images.
The business model Arista Networks specializes in Ethernet switches, which transport data in, out, and between server racks. Those racks contain the AI chips that process intense workloads and enable AI products and services like ChatGPT. All of Arista's switches run on its proprietary software.
Premium Feature
Moneyball Superscore
93/100
Today's Change
(
-0.22
%) $
-0.45
Current Price
$
206.90
The neat thing about the software is that it lets Arista's Ethernet switches easily talk to each other and move data more seamlessly across racks and the data center as a whole. Engineers can make changes to thousands of Arista switches simultaneously instead of making changes to individual switches, which was a nightmare in the early 2000s.
Arista sells more switches when customers need to upgrade their data centers to handle more intense workloads. Old ones need to be replaced. Sales also go up when tech giants need to expand their data centers. More chips require more racks, and more racks translate into additional Ethernet switch sales.
It's a huge pain for any data center to switch from Arista to any competitor. That would mean getting rid of all Arista switches and the critical software that links them all together.
Arista's customers have deep pockets Arista leans heavily on a small number of customers, with Microsoft (MSFT +1.48%) accounting for more than one-quarter of the company's 2025 revenue. Although that type of concentration concerns some investors, Arista's high retention rate and good relationship with hyperscalers are important to keep in mind.
With that issue addressed, it's good to look closer at the customer profile. Microsoft is one of the cloud providers that works with Arista Networks. Amazon (AMZN -0.05%), Alphabet (GOOG +1.02%) (GOOGL +0.86%), and Meta Platforms (META +1.90%) are also customers, and all four of these companies pull in billions of dollars in quarterly profit.
Furthermore, all of these customers have committed to spending more money on artificial intelligence. As their efforts scale, they will need to bolster their AI infrastructure, and that includes buying more of Arista's products.
Those hyperscalers also posted double-digit percentage year-over-year revenue growth rates in their most recent quarters. If growth remains strong, these companies will have no problem pouring more money into Arista's coffers. The broader expansion of AI data centers can also result in new customers that improve diversification.
Revenue growth is trending higher The AI tailwind has benefited many companies, including Arista, and it's visible in financial results. Arista delivered 38% year-over-year revenue growth in the second quarter. It has an annualized revenue growth rate of 27% during the past decade, so the current growth rate is a big deal.
Arista's $3 billion in revenue also marked a 12% sequential boost. Arista Chief Executive Officer Jayshree Ullal touted the results while explaining that customers see Arista as the "central nervous system" for AI infrastructure.
It's not just this quarter, either. Arista has $5.1 billion in short-term deferred revenue, which will become realized revenue by the end of the year. It also has $1.8 billion in long-term deferred revenue.
Its revenue growth is also coming from all key regions. North American revenue increased by 36% year over year, with strong gains also posted in the EMEA and APAC regions. U.S. hyperscalers are driving most of the AI expenditures, but more traction in other parts of the world can help Arista sustain elevated revenue growth rates even if the North American market slows.
However, that slowdown scenario is unlikely anytime soon. Grand View Research projects a 31% compound annual growth rate (CAGR) for the AI industry through 2033, and Arista should be able to ride that momentum to new all-time highs.
Marc Guberti has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Arista Networks, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has a disclosure policy.
Analýza studie fáze 3 MAESTRO-NASH zahrnující 738 pacientů ukázala, že Rezdiffra zlepšila fibrózu a MASH bez ohledu na běžné genetické rizikové varianty.
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression
CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).
The analysis demonstrated that treatment with Rezdiffra resulted in fibrosis improvement, MASH resolution and liver fat and biomarker reductions across patients with several well-established genetic variants associated with MASH progression, including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7. The findings suggest that Rezdiffra may have a therapeutic effect regardless of genetic risk factors that contribute to more severe disease.
“Understanding how common MASH risk alleles may influence a patient’s response to treatment will be increasingly important as the treatment landscape and number of diagnosed patients continue to evolve. For example, there is emerging evidence suggesting that response to various therapies could differ in individuals with MASH carrying the PNPLA3 allele, and it will be important to perform similar analyses for other approved and investigational MASH therapies moving forward,” said Naga Chalasani, M.D., David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine and lead author of the study. “It is encouraging to see that Rezdiffra demonstrated consistent effects on liver histology and biomarkers across the genetic risk subgroups evaluated, supporting broad applicability across patients with this serious liver disease.”
“MASH is a complex, heterogeneous disease driven by both metabolic and genetic factors,” said David Soergel, M.D., Chief Medical Officer of Madrigal. “These data reinforce that Rezdiffra provides broad benefit across patients with MASH, including those with the most common genetic risk variants that may put them at higher risk of disease progression, cirrhosis and liver cancer, strengthening its position as a foundation of MASH treatment. These results also support our pipeline strategy of developing precision approaches targeting well-defined genetic drivers of disease that may complement Rezdiffra in specific patient populations.”
About the Analysis
The publication, “Effects of select MASH risk genotypes on resmetirom efficacy on liver histology and biomarkers in patients with MASH and liver fibrosis: a secondary analysis of the MAESTRO-NASH trial,” reports results from a pre-specified secondary analysis of 738 patients from the Phase 3 MAESTRO-NASH trial who consented to genetic testing and completed baseline and Week 52 liver biopsies. The analysis was not prospectively powered to detect small genotype-by-treatment interactions, and only select common variants were assessed. Across all major efficacy endpoints, including MASH resolution, fibrosis improvement, MRI-PDFF reduction and multiple biomarkers, there was no meaningful difference in treatment response based on MASH genetic risk variants or a composite genetic risk score.
Among the findings:
Resmetirom responses were consistent across PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 risk groups for MASH resolution, fibrosis improvement and MRI-PDFF reduction.The treatment effect remained consistent after accounting for sex and Hispanic ethnicity.Results suggested Rezdiffra's mechanism of action as a thyroid hormone receptor-beta (THR-β) agonist is not affected by common genetic pathways associated with MASH progression and severity.Patients with high-risk genotypes of PNPLA3 or HSD17B13 demonstrated reduced frequency of metabolic risk factors, including diabetes and hypertension, suggesting patients with greater genetic risk could still have high stages of fibrosis, even if they had fewer traditional metabolic risk factors.Because this was a secondary analysis with limited numbers in some genotype groups, smaller genotype-specific effects or rarer variants cannot be excluded.In the overall MAESTRO-NASH trial (n=966), Rezdiffra was generally well tolerated, with the frequency of serious adverse events similar across treatment groups. See additional risk information below. Madrigal's R&D strategy includes developing therapies that target validated disease mechanisms and may complement Rezdiffra’s broad therapeutic effects, especially in patient populations with specific needs. In May 2026, the company announced the addition of MGL-0795 (formerly ARO-PNPLA3), a clinical-stage, small interfering RNA (siRNA) asset targeting PNPLA3 to its pipeline as a potential precision-medicine approach. Mutations in the PNPLA3 gene are strongly associated with MASH progression and a high risk of developing hepatocellular carcinoma (HCC). Madrigal will consult with the FDA on design of a Phase 2 combination trial with Rezdiffra.
In this analysis, MASH resolution in the PNPLA3 subgroup was achieved in 38.4%, 30.8% and 30.5% of Rezdiffra-treated patients, versus 12.9%, 5.1% and 11.7% in patients in the placebo group across low, intermediate and high-risk genotypes, respectively, while fibrosis improvement was 34.2%, 29.5% and 31.4% versus 14.1%, 13.7% and 15.0%, respectively.
About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.
Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis.
Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.
As disease awareness improves and disease prevalence increases, the number of patients diagnosed with F2 to F4c MASH is growing.
About Rezdiffra
What is Rezdiffra?
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.
Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:
have any liver problems other than MASH.have gallbladder problems or have been told you have gallbladder problems, including gallstones.are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby. A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324. are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, because Rezdiffra is not recommended in patients taking these medicines.Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. What are the possible side effects of Rezdiffra?
Rezdiffra may cause serious side effects, including:
liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice) or stomach pain/tenderness.gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach pain, vomiting, dizziness and constipation.
These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324.
Please see the full Prescribing Information, including Patient Information, for Rezdiffra.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.
Forward-Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the therapeutic effect of Rezdiffra across genetic variants associated with MASH, Madrigal’s ability to develop its pipeline and the potential benefit of Madrigal’s pipeline candidates for the treatment of MASH. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; our ability to successfully commercialize Rezdiffra in the U.S. and Europe; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of our clinical trials, including, but not limited to our ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; our ability to protect our intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.
Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.
Madrigal Pharmaceuticals, Rezdiffra® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.
Matador Resources (NYSE: MTDR) dokončil akvizici společnosti Paloma Permian za 1,25 miliardy USD v hotovosti; transakce přidává více než 156 vrtných lokalit a 59 povolení k vrtům.
What happened Matador Resources Company (NYSE: MTDR) closed its previously announced acquisition of Paloma Permian LLC on Oct. 1, 2026, for $1.25 billion in cash.
The target and its subsidiaries own proved undeveloped acreage and oil and natural gas producing properties in Eddy and Lea counties, New Mexico.
The press release says the deal adds over 156 net locations, 59 approved drilling permits and about 16,500 net primarily undeveloped acres. Matador also said it expects to start drilling up to 25 wells tied to the acreage by year-end 2027.
The company said production tied to the acquisition has outperformed its underwriting estimates by about 10% since June 1, 2026.
Key numbers Metric Latest Change Source Purchase price $1.25 billion Matador press release Net locations added over 156 net locations Matador press release Approved drilling permits 59 approved drilling permits Matador press release Net acreage position approximately 240,000 net acres from 203,000 net acres, +37,000 net acres Calculated from Matador press release Expected debt paydown approximately $350 million to $400 million Matador press release Read more: Matador Resources (MTDR) stock analysis and investment case
Why it matters OptimistFi's case is that Matador works if its Delaware Basin acreage and related midstream exposure keep turning drilling and acquisition capital into high-return cash flow per share.
This closing supports that view by adding acreage, drilling inventory and a stated path to debt reduction.
Using the October 2025 base of 203,000 net acres and the fourth-quarter 2026 target of about 240,000 net acres, Matador is up about 37,000 net acres.
That is about 18.2% and shows the deal expands the company's acreage base quickly.
The filing links the payoff to future drilling and operations, not to cash received at closing.
The main caveat is that the free cash flow and debt-repayment benefits are still expected, and the planned paydown is only about $350 million to $400 million depending on commodity prices.
Browse: stock research on every company OptimistFi covers
What's next Matador said it will discuss the Paloma assets in its third-quarter 2026 earnings release and conference call in early November.
It also expects the Ridge Runner Resources II, LLC acquisition to close later this month.
Matador expects to pay down its reserves-based lending credit facility led by PNC Bank after the fourth-quarter closings.
Those updates will show whether the deal is turning acreage into cash flow and debt reduction, or just adding to the asset base.
More from OptimistFi MTDR stock: the Matador Resources thesis, its status and the next test to watch United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources Matador press release on Paloma closing — Announces the closing of the Paloma acquisition and integration details. Matador Form 8-K — Reports completion of the acquisition and furnishes the press release. Read the full OptimistFi thesis on Matador Resources Company: https://optimistfi.com/stocks/MTDR
See what would break the Matador Resources Company thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Matador Resources Company investment case, its status and the next test to watch live on the Matador Resources Company thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
Maximus, Inc. (NYSE:MMS – Get Free Report) declared a quarterly dividend on Monday, October 5th. Investors of record on Friday, November 13th will be paid a dividend of $0.33 per share by the health services provider on Monday, November 30th. This represents a $1.32 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, November 13th.
Maximus has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 2 consecutive years. Maximus has a payout ratio of 19.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Maximus to earn $8.36 per share next year, which means the company should continue to be able to cover its $1.32 annual dividend with an expected future payout ratio of 15.8%.
Maximus Trading Up 3.4% Shares of Maximus stock opened at $54.41 on Tuesday. Maximus has a fifty-two week low of $51.04 and a fifty-two week high of $100.00. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42. The company has a market capitalization of $2.85 billion, a P/E ratio of 8.04 and a beta of 0.59. The company has a fifty day moving average of $57.18 and a 200 day moving average of $60.09.
Maximus (NYSE:MMS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating the consensus estimate of $2.21 by $0.01. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The business’s revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. On average, sell-side analysts anticipate that Maximus will post 8.03 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several research analysts have weighed in on MMS shares. Wall Street Zen downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Maximus in a research report on Monday, August 17th. Finally, Zacks Research raised shares of Maximus from a “strong sell” rating to a “hold” rating in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.
Get Our Latest Stock Report on MMS
About Maximus (Get Free Report)
Maximus, Inc (NYSE:MMS) is a provider of government services and technology-enabled solutions. The company partners with federal, state, provincial and local governments to administer public programs, improve service delivery and support interactions between governments and the people they serve.
Its business activities include health and human services administration, employment and workforce services, child support and eligibility services, customer contact centers, program management, consulting and digital transformation.
See Also Five stocks we like better than Maximus NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
SAN FRANCISCO--(BUSINESS WIRE)--All Remote-- GitLab Inc., the intelligent orchestration platform for DevSecOps, today announced new capabilities for the governed software factory, a connected system for moving software from idea to production under an organization's own policy and standards. These new innovations are designed to help organizations ship more AI-generated software to production without taking on more risk or cost.
More than 70 million developers and over 10,000 enterprises innovate on GitLab today. Over the last three months on GitLab, active users of agentic software development grew 200% year over year, while secure repositories grew 100%, user namespaces grew 80%, and CI/CD pipelines grew 40%.
Yet most organizations are running a shadow software factory built from separate tools for coding, issue tracking, source code management, CI/CD pipelines, security, artifact management, and deployment.
These systems have no shared identity, common policy, or a record of how a change was made. That fragmentation slows handoffs, breaks context between stages, and prevents engineering leaders from tracing changes from plan to production or measuring the true impact of their AI investments.
GitLab connects those steps so agents can work within an organization's context, workflows, and guardrails, while creating an evidence chain that records how changes move from intent to production. Together, these capabilities form the foundation of a governed software factory, helping organizations move from intent to production with fewer handoffs, stronger safeguards, and clearer visibility into what AI delivers.
Orchestrating Agentic Workflows Across the Software Lifecycle
Agentic software development can stall after coding when reviews, tests, security checks, approvals, and deployments require handoffs between people, tools, and stages.
Goal-driven flows in GitLab Duo Agent Platform, powered by /goal in Duo CLI, in headless mode and in Duo Agentic Chat, and the GitLab for Slack app, eliminate waits between handoffs across the software lifecycle.
Custom Flows and flow triggers automate multi-step work under the same identity, policy, and evidence chain. Teams can start and follow the same flows from the tools and channels they already use, under the same identity and policy.
Assembling the Right Software at Agent Scale
Most software that organizations ship is assembled from open-source packages, base images, and libraries. Builds fail when pipelines assemble the wrong or missing components, and agents multiply that failure rate by publishing packages at machine speed across vendor and project registries that carry their own rules.
GitLab Artifact Central, now in beta on GitLab.com with availability on GitLab Self-Managed planned for later this month, lets platform teams assemble the right software the first time. It brings containers and packages into one control plane alongside source code management and CI pipelines. With GitLab Artifact Central, teams set policy once at the organization level, instantly answer what was published, and realize up to 50% lower total cost of ownership compared with alternative tooling.
Securing the Software Factory at Machine Speed
As organizations adopt agentic software development, more code, packages, and credentials move through the software supply chain than security teams can review. Agents can pull unvetted packages into a build or reuse credentials stored in local environments, and each vulnerability that stays open increases the risk of exploitation. At machine speed, agents need a foundation they can prove before they earn more autonomy.
To meet the challenge, GitLab is adding security controls to govern what enters a build, to protect credentials each job can reach, to harden the defensive posture for software delivery, and is providing the best practices engineering leaders can use to assess their risk posture for agentic software development.
GitLab Dependency Firewall, available in early access, checks every package against policy before it enters a build. It warns, blocks, or quarantines packages based on rules the organization sets for package age, vulnerability severity, malicious package detection, and license compliance. One control plane spans source, build, and registry, helping teams trace exposure to affected projects and prioritize remediation in minutes instead of weeks.
GitLab Secrets Manager, generally available on GitLab.com and on GitLab Self-Managed in the 19.5 release, secures build-time secrets in one place, and scopes each secret to the job that needs it. It applies existing group and project permissions, and records every event in the GitLab audit trail. With GitLab Secrets Manager, teams can revoke a leaked credential in one click, and realize up to 50% savings compared to hosting a separate vault.
Anthropic’s Claude Mythos 5 and 5.1 will be available within new GitLab Duo Agent Platform security flows next month, helping organizations with approved environments find and fix vulnerabilities faster than attackers can discover and exploit them.
The GitLab Security Standard, available today, gives security and engineering leaders a way to assess their security posture, build trust in autonomous agents through verifiable outcomes, and protect software already in production. The standard sets five controls for the agentic era and uses time from detection to verified remediation as its core metric.
Optimizing Agentic Workflows for Context and Cost
AI investment is difficult to manage when leaders cannot connect credits consumed to outcomes delivered. Without that evidence, prioritizing the next use case and setting spending limits becomes guesswork. Agentic workflows also incur unnecessary cost when they lack the lifecycle context needed to complete a task, leading to more retries and higher token consumption.
GitLab addresses these challenges by giving agents the lifecycle context they need to work more efficiently and leaders clear visibility into AI cost and impact.
Since its beta announcement in June, GitLab Orbit has been used by more than 3,500 organizations and supported over 280,000 queries from their coding agents. It maps the entire software lifecycle into real-time knowledge that agents can act on, enabling them to complete tasks with up to 45x fewer retries and 4.5x fewer tokens. Orbit will reach general availability next month across all GitLab deployment options.
Duo Agent Platform Impact Analytics, now in early access, shows cost and impact of AI investment by team, task, and model. Impact Analytics complements the recently introduced AI usage caps and controls, which allows platform admins to set spending ceilings at the subscription, group, or user level. Teams see their adoption metrics, results of agentic workflows, and credit consumption alongside the real work that reaches production. This level of visibility is made available even when using a mix of AI models with Duo Agent Platform: GitLab-managed frontier and open-weight models, or self-hosted.
To learn more, please read the what's new page.
Supporting Quotes
"GitLab Secrets Manager lets us centralize secrets across CI/CD, Kubernetes, and infrastructure as code without standing up multiple vaults or maintaining separate integration points," said Jeremy Nauta, software architect, OneTrust. "It also strengthens our supply chain security by tightening which users and pipelines can access a given credential." “When defenders have more context than attackers, advanced models change the math in their favor,” said Rajat Pandit, Head of Applied AI at Anthropic. “GitLab’s customers will be able to use Claude Mythos 5 and 5.1 to find vulnerabilities and verify fixes inside the workflows they already run.” "Every enterprise already runs a software factory, but few have intentionally designed the systems and controls that govern it," said Manav Khurana, chief product and marketing officer at GitLab. “GitLab brings together the foundational building blocks for a governed software factory, connecting agentic workflows, security, and AI context and controls so organizations can move software from intent to production with greater speed, governance, and visibility.” About GitLab
GitLab is the intelligent orchestration platform for DevSecOps. GitLab enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. More than 70 million registered users and approximately 50% of the Fortune 100* trust GitLab to ship better, more secure software faster.
*Fortune 500® is a registered trademark of Fortune Media IP Limited, used under license. Claim based on GitLab data. Fortune 100 refers to the top 20% ranked companies in the 2025 Fortune 500 list, published in June 2025. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of GitLab.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although we believe that the expectations reflected in the forward-looking statements contained in this release are reasonable, they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results or outcomes to be materially different from any future results or outcomes expressed or implied by the forward-looking statements.
Further information on risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those included in or contemplated by the forward-looking statements contained in this release are included under the caption “Risk Factors” and elsewhere in the filings and reports we make with the Securities and Exchange Commission. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
SUBSCRIBE uzavřel partnerství s FactSet, které propojí správu investic na soukromých trzích s platformou FactSet pro institucionální investory a správce majetku.
Integration streamlines investor onboarding to private funds, digitalizes fund subscriptions, and centralizes investment reporting for institutional investors wealth managers
, /PRNewswire/ -- SUBSCRIBE, the global fintech company providing the leading enterprise operating system for alternative investments, today announced a strategic partnership with FactSet (NYSE: FDS| NASDAQ: FDS), a leading global data and AI solutions provider to the financial markets. The partnership integrates SUBSCRIBE's private markets workflow and data solution into FactSet's leading platform for trusted data, research, & analytics, and advisor and client intelligence, delivering an end-to-end private markets experience for institutional investors and wealth managers.
The integration provides FactSet's clients with seamless investor onboarding to private funds, digitalized fund subscriptions, and centralized post-trade investment reporting, enabling investors to manage, analyze, and monitor private and public investments side by side within a single platform.
"Our goal has always been to rebuild the critical infrastructure and data layers required for managing private market fund investments," said Rafay Farooqui, Founder and CEO of SUBSCRIBE. "FactSet is one of the investment and wealth management industries' leading providers of portfolio performance, risk analytics, and reporting software. Together, we can deliver a truly superior end-to-end experience to institutional and wealth management investors at scale."
"This partnership creates meaningful value for our clients, streamlining and synthesizing data for greater visibility into private market portfolios," said Greg King, Senior Director and Head of Wealth Management at FactSet. "As inflows to alternative investments continue to grow, our integrated offering with SUBSCRIBE is uniquely positioned to deliver value across the total portfolio, including both public and private investments."
SUBSCRIBE currently serves both institutional investment and wealth management firms, supporting over $6 trillion in private market assets for leading institutional investors and alternative asset managers, and more than 55,000 financial advisors across 1200 wealth management firms. The partnership extends SUBSCRIBE's reach to FactSet's more than 8,600 global clients and 219,000 individual users, equipping them with alternative investment workflow tools embedded directly into their existing research, analytics, and investment processes.
For more information, visit www.subscribeplatform.com or www.factset.com.
About SUBSCRIBE
SUBSCRIBE is a fintech company digitally transforming the landscape of alternative investments for alternative asset managers, institutional investors, wealth managers, law firms, and fund administrators. Our platform technology modernizes the archaic infrastructure of private fund investments by delivering a central operating system — catering to every role within the investment process empowering them to connect any fund, any investor, anywhere in the world on a single platform. SUBSCRIBE supports over $6 trillion in private market assets and is the trusted technology partner to thousands of firms that rely on our end-to-end enterprise solution to scale their private market investment programs and manage investment processes across pre-trade, trade, and post-trade fund workflows. For additional information, visit www.subscribeplatform.com or follow the company on LinkedIn.
PacBio a TychoBio budou analyzovat více než 10 000 vzorků pomocí sekvenování HiFi a Kinnex k trénování modelů AI navrhujících RNA terapie pro léčbu vzácných onemocnění.
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio’s drug discovery models | Source: PacBio
MENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio HiFi sequencing and Kinnex long-read RNA sequencing to generate data from more than 10,000 samples, building large-scale datasets linking the design of steric blocking antisense oligonucleotides (SBOs) to their effects across the transcriptome, with plans to expand the approach to siRNA and other RNA-targeting compounds.
TychoBio will test candidate RNA therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. Those results will become training data for models designed to predict which compounds are most likely to work, how long their effects may last, and where unintended effects may occur.
Training models for maximizing on-target efficacy and effect duration of SBOs requires an in-depth understanding of the interaction between SBOs and the cell’s transcriptome. By more fully characterizing the effect of SBOs in various cell lineages, TychoBio will unlock new insights into RNA regulation and SBOs mechanism of action, accelerating the development of safer and more efficient therapeutic designs.
“AI models are only as good as the data they are trained on. To effectively identify new rare disease treatments, we needed the highest quality biological data, which can only be generated using PacBio HiFi sequencing technology,” said Felix Raimundo, founder and CEO of TychoBio. “HiFi long read sequencing lets us see across full-length transcripts, including changes in isoforms and splicing of how the transcriptome is affected in rare diseases and which treatments could modify disease processes.”
PacBio has partnered across the rare disease community to support the characterization, diagnosis and development of therapeutics to address the global burden of rare disease including through its global HiFiSolves Consortium, the n-Lorem Foundation and EspeRare, the GREGoR Consortium, Care4Rare Canada Consortium, the Genetic Alliance, Genomics England, and many academic collaborations. The company’s Kinnex products, alongside HiFi sequencing, enable screening of thousands of sequences in multiple cell lineages as well as the development of models of both efficacy and toxicity, which are critical to advance potential rare disease therapies out of the laboratory and into patient clinical trials.
“Our work with TychoBio, like our collaboration with Basecamp Research, highlights the critical value that high-quality sequencing data plays in generating the foundational data that will power biological modeling in the AI ecosystem,” said Mark Van Oene, President and Chief Executive Officer of PacBio. “We believe that this critical work will enable the development of transformative therapies that ultimately improve the lives of patients with rare diseases and their families.”
The collaboration puts HiFi data directly into the research workflow for designing RNA therapeutics for rare diseases.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About TychoBio
TychoBio is a frontier biology company that designs RNA therapeutics. Our data-generation platform unlocks scaling laws for gene therapies. We are bringing in therapeutic abundance to previously ignored patient populations. For more information, please visit www.tychobio.ai and follow @tychobio_ai.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and TychoBio; plans related to potential therapy development and design, acceleration of safer and more efficient therapeutic designs and development, dataset generation, types of data generated, sequencing at least 10,000 samples, expansion to other compounds, and impact on rare disease characterization and diagnosis; transforming long-read sequencing data into meaningful genomic insights; value of high-quality sequencing data in AI ecosystem biological modeling; HiFi data being directly in the workflow for RNA therapy design for rare diseases; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using new technologies; potential product performance and quality issues; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Společnost e-STORAGE ze skupiny Canadian Solar dodá společnosti OX2 v Novém Jižním Walesu bateriový systém o výkonu 100 MW a kapacitě 200 MWh; zahájení komerčního provozu je plánováno na třetí čtvrtletí roku 2028.
, /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e‑STORAGE, its energy storage solutions business, has signed an agreement to supply and commission a 100 MW/200 MWh battery energy storage system (BESS) for OX2's Muswellbrook Solar Farm and Battery, a solar-plus-storage project in New South Wales, Australia. Shipments are scheduled to begin in Q3 2027, with commercial operation targeted for Q3 2028. The battery cells and SolBank system will be produced in-house at Canadian Solar's manufacturing facilities, giving the customer end-to-end supply chain visibility and ensuring strict quality control across the product.
e‑STORAGE will deliver an integrated solution built on SolBank 3.0 battery containers, paired with Power Conversion Systems (PCS), plant controls, and the Company's proprietary EQ-S Energy Management System (EMS) developed and built in-house by e‑STORAGE's North American software team. e‑STORAGE will be responsible for the R1 grid connection studies, supply the hybrid power plant controller that coordinates the battery with the co-located solar farm, and lead the overall integration and commissioning of the hybrid project. The arrangement is backed by a 20-year long-term service agreement (LTSA), placing hardware, proprietary software, and long-term performance under a single accountable partner.
The project sits roughly 2.5 kilometers east of Muswellbrook, on land at a former coal mine within the Hunter-Central Coast Renewable Energy Zone. The location is significant: as the region's aging coal generators wind down toward retirement in the early 2030s, the dispatchable capacity they once provided must be replaced. Two-hour storage fills that gap directly, holding midday solar output and releasing it into the evening demand peak when supply from retiring thermal plants tightens.
Once operational, the system will support the long-term hybrid power purchase agreement OX2 has signed for the project, converting variable solar output into firm, contracted supply. By storing and dispatching solar energy on demand, the BESS strengthens grid reliability in a region transitioning away from coal and helps deliver firm renewable power to the communities in the Hunter Region.
Steve Symons, Vice President, OX2 Australia, said: "This battery storage system is what turns Muswellbrook into a true hybrid facility — pairing solar generation with storage so we can capture energy when the sun is shining and deliver it when the grid needs it most. It's a key step in providing firm, reliable renewable power to the Hunter region."
Jeff Roy, President of e‑STORAGE, said: "Australia's energy transition is being decided in regions like the Hunter, where storage now has to carry the load that retiring coal once did. We control this project from the cell through to our own energy management software and 20 years of service, which means OX2 has one partner accountable for how the system performs over its full life."
About Canadian Solar Inc.
Canadian Solar is one of the world's largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 25 years, Canadian Solar has successfully delivered nearly 180 GW of premium-quality solar photovoltaic modules to customers across the world. Through its energy storage solutions business e-STORAGE, Canadian Solar has shipped over 23 GWh of battery energy storage solutions to global markets and had a contracted backlog of $3.5 billion as of June 30, 2026. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 12.4 GWp of solar power projects and 6.4 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes approximately 22 GWp of solar and 84 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.
About e-STORAGE
e-STORAGE is a subsidiary of Canadian Solar and a leading company specializing in designing, manufacturing, and integrating battery energy storage systems for utility-scale applications. e-STORAGE offers proprietary battery energy storage systems (BESS) spanning battery cells, battery PACKs, power conversion systems (PCS), energy management systems (EMS) and system integration. It also provides comprehensive EPC services and full-lifecycle station operation and asset management, helping customers improve grid operations across the project lifecycle. For more info, please refer to the Media&PR section of www.csestorage.com and follow our LinkedIn page.
Safe Harbor/Forward-Looking Statements
Certain statements in this press release, including those regarding the Company's expected future shipment volumes, revenues, gross margins, and project sales are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially. These statements are made under the "Safe Harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as "may", "will", "expect", "anticipate", "future", "ongoing", "continue", "intend", "plan", "potential", "prospect", "guidance", "believe", "estimate", "is/are likely to" or similar expressions, the negative of these terms, or other comparable terminology. These forward-looking statements include, among other things, our expectations regarding global electricity demand and the adoption of solar and battery energy storage technologies; our growth strategies, future business performance, and financial condition; our transition to a long-term owner and operator of clean energy assets and expansion of project pipelines; our ability to monetize project portfolios, manage supply chain fluctuations, and respond to economic factors such as inflation and interest rates; our outlook on government incentives, trade measures, regulatory developments, and geopolitical risks; our expectations for project timelines, costs, and returns; competitive dynamics in solar and storage markets; our ability to execute supply chain, manufacturing, and operational initiatives; access to capital, debt obligations, and covenant compliance; relationships with key suppliers and customers; technological advancement and product quality; and risks related to intellectual property, litigation, and compliance with environmental and sustainability regulations. Other risks were described in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 20-F filed on April 10, 2026. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and Canadian Solar undertakes no duty to update such information, except as required under applicable law.
Canadian Solar Inc. Investor Relations Contact
Wina Huang
Investor Relations
Canadian Solar Inc.
[email protected]
Společnost Levi Strauss má ve třetím čtvrtletí vykázat zisk 36 centů na akcii a tržby ve výši 1,62 miliardy USD, oproti 34 centům na akcii a tržbám 1,54 miliardy USD před rokem.
Levi Strauss & Co. (NYSE:LEVI) will release its third-quarter earnings report after the closing bell on Wednesday, Oct. 7.
Some of the apparel company’s investors may be eyeing potential dividend gains. Currently, Levi Strauss has an annual dividend yield of 3.16%, with a quarterly dividend of 16 cents per share (64 cents a year).
To earn $500 monthly from Levi Strauss, we start with a yearly target of $6,000 ($500 x 12 months).
Next, we divide that amount by LEVI’s $0.64 dividend: $6,000 / $0.64 = 9,375 shares.
So, an investor would need to own approximately $190,031 worth of Levi Strauss, or 9,375 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.64 = 1,875 shares, or $38,006 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as dividend payments and stock prices both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Levi Strauss Price ActionAnalysts expect the company to report quarterly earnings of 36 cents per share, up from 34 cents per share a year ago. The consensus estimate for LEVI’s quarterly revenue is $1.62 billion. It reported $1.54 billion last year, according to Benzinga Pro.
Ahead of quarterly earnings, Jefferies analyst Blake Anderson maintained a Buy rating on Levi Strauss on Oct. 1 and cut the price target from $27 to $25.
Shares of Levi Strauss gained 2% to close at $20.27 on Monday.
Společnost Worksport přijala v srpnu objednávky v hodnotě 2,92 mil. USD, což představuje meziměsíční nárůst o 16,4 %; anualizované tempo objednávek dosáhlo 35,05 mil. USD.
August orders increase 16.4%, while estimated backlog grows 145.1% to approximately $898,000. Preliminary net sales reach $2.34 million, extending the Company's eight-month sales climb
WEST SENECA, NY / ACCESS Newswire / October 6, 2026 / Worksport Ltd. (Nasdaq:WKSP) ("Worksport" or the "Company"), a U.S.-based innovator and manufacturer of hybrid and clean energy solutions primarily for the light truck, overlanding, and global consumer goods markets, today announced preliminary August 2026 sales orders of approximately $2.92 million, an increase of 16.4% from July 2026, representing an annualized sales-order run rate of $35.05 million. Preliminary net sales increased 5.6% to $2.34 million, while estimated month-end backlog rose to approximately $898,000, reflecting order intake that exceeded invoicing during August.
Monthly Net Sales Extend Eight-Month Climb
Worksport's preliminary monthly net sales increased from approximately $937,000 in January to $2.34 million in August, representing growth of approximately 150%. Each successive month exceeded the previous month across the January-to-August period, with monthly growth averaging approximately 14.6% across 2026.
August sales orders increased 16.4% from approximately $2.51 million in July to approximately $2.92 million, while invoiced sales increased 5.6% from approximately $2.27 million in July to approximately $2.39 million. August orders exceeded invoicing by approximately $532,000, increasing Worksport's estimated backlog from an updated July balance of approximately $366,000 to $898,000, a 145.1% increase.
Annualized Sales-Order Run Rate Increases to $35.05 Million
Based on August sales orders, Worksport's annualized sales-order run rate increased to approximately $35.05 million, compared with approximately $30.13 million using the updated July order figure. This represents an increase of approximately $4.93 million, or 16.4%.
August marked the fourth consecutive month with preliminary gross margin above 30%, as higher sales generated additional gross profit alongside margin expansion.
CEO Commentary
"Our approximately $35 million annualized sales-order run rate reflects growing demand and a meaningful opportunity to move Worksport toward positive operating cash flow," said Steven Rossi, Founder and Chief Executive Officer of Worksport. "We have now maintained preliminary gross margin above 30% for four consecutive months. If we sustain that margin strength while growing revenue, we can generate more gross profit to cover operating expenses and narrow the gap to positive operating cash flow. Higher production volumes should also help us spread fixed manufacturing costs across more units, supporting further margin improvement as we scale. Our priority is to convert this higher order pace into shipments and cash while keeping spending disciplined, so revenue growth translates into a financially stronger business for shareholders."
Stay tuned for more information and join our mailing list to stay up to date with the latest: Join Worksport's Newsletter
Connect with Worksport Chief Executive Officer, Steven Rossi
Steven Rossi LinkedIn | Note: CEO Steven Rossi has terminated the use of X (formerly Twitter)
About Worksport
Worksport Ltd. (Nasdaq:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport's hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy's website is terravisenergy.com.
Connect with Worksport
Please follow the Company's social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram, the links of which are links to external third-party websites, as well as sign up for the Company's newsletters at investors.worksport.com.
Social Media Disclaimer
The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to its investors using its investor relations website, press releases, Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.
Supplemental Operating Metrics and Preliminary Results
The Company presents sales orders, invoiced sales, estimated backlog and annualized run rates to provide additional context on demand and operating trends alongside its U.S. GAAP financial results. Management uses sales orders, invoiced sales, backlog and annual run rates to evaluate operating performance and support strategic decisions. These metrics are not substitutes for recognized net sales and may differ from similarly titled metrics used by other companies.
Sales orders represent the value of orders received and recorded during the applicable month. Invoiced sales reflect monthly invoicing before applying certain discounts. Estimated backlog is derived from sales orders and invoicing totals using a first-in, first-out allocation assumption, rather than an order-level analysis of fulfillment dates. These metrics are distinct from recognized net sales; conversion of sales orders and estimated backlog to revenue depend on fulfillment and satisfaction of applicable revenue-recognition requirements.
Annualized run rates multiply the applicable month's sales orders or preliminary net sales by twelve. The annualized run rates for sales orders calculation includes all sales orders received during that month, some of which may be in backlog. These calculations assume a constant monthly pace and are illustrative. The calculations do not reflect annual recurring revenue, a committed 12-month order book, full-year revenue guidance, or forecasts of future performance.
The monthly financial information in this release is preliminary and unaudited, remains subject to accounting close and review procedures, and may differ from final reported results.
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. Forward-looking statements in this release include expectations regarding order conversion, production volumes, gross margin improvement and progress toward positive operating cash flow. When used in this press release, the words "anticipate," "believe," "estimate," "scheduled," "expect," "future," "intend," "plan," "project," "envisioned," "should," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; (iv) competition from other producers of similar products; and (v) order cancellations or fulfillment delays, production constraints and working-capital requirements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances, except as required by applicable law.
Players can gain a better understanding of their overall game with biometric data, swing metrics, green reading and more to help them achieve peak performance
, /PRNewswire/ -- /PR Newswire – Garmin (NYSE: GRMN) today unveiled its new flagship golf smartwatch, Approach® S72, a premium, feature-rich companion on the course that also provides advanced health and wellness features for everyday wear. Available in two sizes – 43mm and 47mm – with bright AMOLED displays, the smartwatch includes a new lightweight ComfortFit fabric band, titanium bezel and sapphire lens to ensure all-day comfort and durability. With biometric data1, including real-time heart rate, golfers can gain a better understanding of how their heart rate changes before and after each shot. What's more, Approach S72 adds on-wrist swing metrics to help players implement changes to their swing based on real data rather than just feel.
Players can gain a better understanding of their overall game with biometric data, swing metrics, green reading and more to help them achieve peak performance. Players also have access to a new feature to give them a better understanding of green contour data. With an active Garmin Golf Membership™, golfers can see what direction putts will break and the average slope percentage on select courses, making it quicker and easier to determine their aim point.
"We're excited to introduce the next generation of golf technology with Approach S72 and help golfers better understand their whole game. From biometric data and swing metrics to advanced golf features and everyday smartwatch tools, Approach S72 gives avid golfers the insights they need to take their game to the next level. It's everything players would want in a golf watch and an everyday smartwatch."
–Susan Lyman, Garmin Vice President of Consumer Sales and Marketing
New features for the course
Golf biometric data: Look back on a completed round and see trends in how heart rate may have impacted the score1. Swing metrics: Golfers can receive advanced insights into their swing with swing metrics, including hand speed, backswing length, wrist rotation and more. Green reading: Golfers can be more confident in their aim point with the green reading feature on select courses, which uses green contour data to make it easier to find the line2. Driving range activity: Not only track swing metrics and learn tendencies but also log driving range activities into the Garmin Connect™ app, so players' practice sessions contribute to their fitness goals. Putting analytics: Receive insights in the Garmin Golf app following a round on speed bias, direction bias, make rate and more to help evaluate strengths and weaknesses on the green2. Aerial imagery: Get an enhanced view of the shot ahead with real imagery of the hole to make more informed decisions about where to layup, the best place to miss and more2. Built for all-day wear
Premium build: Constructed with a lightweight titanium bezel that won't hinder a golf swing, the device also features a sapphire lens for durability and a ComfortFit fabric band to ensure a perfect fit on the golfer's wrist. Speaker and microphone: Make and take phone calls and perform basic tasks – on and off the course – with voice commands on Garmin's first golf smartwatch to offer these attributes. Built-in flashlight: Find equipment in the golf bag or illuminate a dark area with a flashlight with variable intensities of white light and a red light. Battery life: Play multiple rounds without needing to re-charge as the larger smartwatch boasts up to 20 hours of battery life on the course and up to 16 days when the GPS is turned off. Maximize performance
Designed for wear both on and off the links, the Approach S72 includes many top-tier fitness features to help golfers improve their overall health and reach peak form each round. Players can get a complete health picture with wrist-based heart rate, stress tracking, Body Battery™ energy monitoring, advanced sleep monitoring and more1. The smartwatch also includes a full complement of preloaded activity profiles to help players work on their strength and mobility.
The Approach S72 golf smartwatches are available now with suggested retail prices starting at $799.99. Learn more about Garmin's full lineup of golf products here.
Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garmin on social, or follow our blog.
1This is not a medical device and is not intended for use in the diagnosis or monitoring of any medical condition; see Garmin.com/ataccuracy.
2Requires an active Garmin Golf membership.
About Garmin: Garmin Ltd. (NYSE: GRMN) is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin and Approach are registered trademarks and Garmin Golf, Garmin Connect and Body Battery are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Media Contacts:
Mike Cummings and Elise Jessee
913-397-8200
[email protected]
Garmin představil chytré GPS hodinky Enduro 4 se solárním nabíjením, výdrží až 320 hodin v režimu aktivity a doporučenou maloobchodní cenou 899,99 USD.
Comprehensive power modes, enhanced stamina metrics, a ComfortFit Fabric Band and Garmin Epic help endurance athletes and multiday adventurers train, race and explore even farther
, /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Enduro™ 4, its longest-lasting GPS smartwatch with solar charging, which includes dynamic features and capabilities to take endurance enthusiasts farther on their next expedition. Utilizing an energy-efficient 1.4" MIP display in combination with a solar lens, Enduro 4 has up to 320 hours of battery life in activity mode1 or up to 90 days of battery life in smartwatch mode2. It also leverages innovative updates like grade-adjusted pace-based workout targets, grade-adjusted rolling pace, stamina zones, stamina curve and Garmin Epic multiday activity logging.
Comprehensive power modes, enhanced stamina metrics, a ComfortFit Fabric Band and Garmin Epic help endurance athletes and multiday adventurers train, race and explore even farther. "As interest and participation in ultra-endurance activities continue to grow, Enduro 4 is designed for athletes and adventurers who want gear they can trust to perform through every mile, every climb and every challenge. Intuitive features like comprehensive power modes make the most of the long-lasting battery life, while grade-adjusted metrics add a new dimension to preparing for hilly or mountainous terrain."
—Susan Lyman, Garmin Vice President of Consumer Sales and Marketing
Grade-adjusted features, stamina metrics and more
In addition to 100+ activity profiles, Enduro 4 introduces new capabilities to the Enduro line, optimized for trail runners, multiday hikers and backpackers, and endurance athletes.
Comprehensive power modes provide preset options to optimize battery life and performance based on the needs of the user. Configurations include Max Accuracy, which offers full-feature tracking for shorter efforts, and Max Battery, ideal for extended activity recording (up to 320 hours with solar charging). Grade-adjusted pace-based workout targets help athletes maintain the right effort range on hilly terrain, while grade-adjusted rolling pace provides a real-time view of pace over varying terrain. Stamina zones show athletes how their stamina impacts an activity, and stamina curve helps users understand how their endurance changes over time based on fitness and training history. With 50% more RAM than Enduro 3 and a more powerful, updated map engine, navigation is easier than ever with 30% faster panning and a smoother, more intuitive map interface for built-in routable maps. Perspective view provides more detail, both close-up and further away, allowing users to better anticipate what comes next. Garmin Epic allows athletes to combine multiple activities into one cohesive story in Garmin Connect™. Activities can be grouped together over days, weeks or months to create an "Epic", which enables users to add photos and share with family and friends, as well as see health and performance data aggregated during that period. Enhanced rowing tools provide additional training insights like VO2 max and power curve for indoor rowing activities, while expanded rucking features let users adjust pack weight during an activity and set target metrics like calories burned. Premium design for maximum versatility
Enduro 4 weighs in at an incredible 66 grams, making it one of the lightest ultraperformance smartwatches on the market. With a 51mm case, Power Sapphire™ scratch-resistant lens, titanium bezel and lightweight fiber-reinforced polymer case, it is built for the demands of the longest races and most taxing adventures, remaining remarkably light on the wrist. An integrated LED flashlight includes both white and red-light options, while a 10 ATM water resistance rating enables confident use in challenging environments.
New to Enduro 4, the ComfortFit Fabric Band combines exceptional comfort, durability and moisture-wicking performance with QuickFit™ functionality, making adjustments and swapping bands even simpler. 64 GB of memory gives users more room for onboard maps, music and data, making it easier to stay prepared for extended adventures away from home.
Available now, Enduro 4 has a suggested retail price of $899.99. Learn more at Garmin.com.
Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garminoutdoor on social, or follow our blog.
1 Assumes continuous use for entire period in 50,000 lux conditions and typical use with activity mode (extended battery) selected
2 Assumes all-day wear with 3 hours per day outside in 50,000 lux conditions
About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark and Enduro, Garmin Connect, Power Sapphire and QuickFit are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
MEDIA CONTACTS:
Elliott Scott
913-397-8200
[email protected]
Trust Division společnosti Central Pacific Bank ve třetím čtvrtletí zvýšila svůj podíl ve společnosti Seagate Technology o 111,7 % na 2 380 akcií v hodnotě 2,195 mil. USD.
Central Pacific Bank Trust Division boosted its holdings in Seagate Technology Holdings PLC (NASDAQ:STX – Free Report) by 111.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,380 shares of the data storage provider’s stock after buying an additional 1,256 shares during the period. Central Pacific Bank Trust Division’s holdings in Seagate Technology were worth $2,195,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC increased its position in Seagate Technology by 70.6% during the second quarter. Retirement Wealth Solutions LLC now owns 29 shares of the data storage provider’s stock worth $28,000 after purchasing an additional 12 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Seagate Technology during the 2nd quarter valued at $39,000. Trust Co. of Vermont acquired a new stake in shares of Seagate Technology during the 2nd quarter worth $54,000. Triumph Capital Management increased its holdings in shares of Seagate Technology by 93.5% during the 2nd quarter. Triumph Capital Management now owns 60 shares of the data storage provider’s stock worth $58,000 after buying an additional 29 shares during the last quarter. Finally, Cornerstone Financial Management LLC raised its position in shares of Seagate Technology by 109.7% in the 2nd quarter. Cornerstone Financial Management LLC now owns 65 shares of the data storage provider’s stock worth $63,000 after buying an additional 34 shares during the period. Hedge funds and other institutional investors own 92.87% of the company’s stock.
Seagate Technology Stock Performance Shares of STX opened at $887.09 on Tuesday. The firm has a market cap of $201.72 billion, a price-to-earnings ratio of 63.91 and a beta of 2.06. The company has a quick ratio of 1.17, a current ratio of 1.67 and a debt-to-equity ratio of 1.56. The business’s 50 day moving average is $856.07 and its two-hundred day moving average is $782.73. Seagate Technology Holdings PLC has a 52-week low of $209.00 and a 52-week high of $1,145.00.
Seagate Technology (NASDAQ:STX – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The data storage provider reported $5.71 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.61. The firm had revenue of $3.63 billion for the quarter, compared to the consensus estimate of $3.50 billion. Seagate Technology had a net margin of 26.11% and a return on equity of 369.98%. The firm’s revenue was up 48.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.59 EPS. Seagate Technology has set its Q1 2027 guidance at 7.100-7.500 EPS. Analysts forecast that Seagate Technology Holdings PLC will post 35.7 EPS for the current fiscal year. Seagate Technology Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Thursday, September 24th will be issued a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Thursday, September 24th. Seagate Technology’s payout ratio is 21.33%.
Key Seagate Technology News Here are the key news stories impacting Seagate Technology this week:
Positive Sentiment: Analysts call the Toshiba-related selloff overdone. Bernstein described the market reaction as a “storm in a teacup,” while other analysts characterized the decline as a potential buying opportunity. The view is that Toshiba’s capacity expansion will take time and may not significantly affect Seagate’s near-term results. Western Digital Jumps 7%, Seagate Climbs 5% as Bernstein Calls Toshiba Selloff a Storm in a Teacup Positive Sentiment: AI infrastructure demand remains the central bullish thesis. Cloud providers building data centers need substantially more high-capacity storage, and Seagate reportedly has nearline-drive contracts extending deep into 2027. Limited industry supply could support utilization, pricing and revenue visibility. Seagate Is Riding One of AI’s Most Important Trends Positive Sentiment: Seagate’s recent operating momentum has been strong. The company’s stock substantially outperformed the S&P 500 over the past year, reflecting investor confidence in its exposure to AI-driven data-center demand. What Was Seagate Telling You Before Its Stock Ran? Neutral Sentiment: The key debate is supply versus demand. Toshiba intends to double HDD production capacity, but investors are assessing how quickly that capacity will come online and whether AI-related demand can absorb the additional drives. Why Western Digital and Seagate Stocks Are Rebounding on Monday? Negative Sentiment: Toshiba’s planned capacity increase remains a longer-term competitive risk. If the expansion materially increases HDD supply, it could eventually pressure Seagate’s pricing, margins and market share. Toshiba Is Doubling Hard Drive Output Negative Sentiment: Reports also cited insider selling. Such activity can weigh on sentiment, particularly after a major rally, although the primary catalyst discussed in the recent coverage was Toshiba’s production announcement. Seagate Technology Shares Gap Down on Insider Selling Wall Street Analyst Weigh In Several equities research analysts have commented on STX shares. Susquehanna upped their price target on Seagate Technology from $775.00 to $875.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $1,300.00 target price on shares of Seagate Technology in a research note on Wednesday, July 29th. Barclays boosted their price target on Seagate Technology from $1,000.00 to $1,250.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Citigroup upped their price target on Seagate Technology from $1,240.00 to $1,300.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Seagate Technology from $1,095.00 to $1,240.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $986.00.
Check Out Our Latest Stock Report on STX
Insider Transactions at Seagate Technology In other Seagate Technology news, EVP John Morris sold 9,354 shares of Seagate Technology stock in a transaction on Monday, September 21st. The shares were sold at an average price of $877.91, for a total value of $8,211,970.14. Following the completion of the transaction, the executive vice president owned 22,693 shares of the company’s stock, valued at $19,922,411.63. The trade was a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ban Teh sold 52,730 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $782.08, for a total transaction of $41,239,078.40. Following the completion of the transaction, the executive vice president owned 5,810 shares in the company, valued at approximately $4,543,884.80. The trade was a 90.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 466,959 shares of company stock valued at $378,840,741. 0.51% of the stock is currently owned by insiders.
Seagate Technology Company Profile (Free Report)
Seagate Technology Holdings plc is a data storage technology company that designs, manufactures and supplies solutions for storing, managing and accessing digital information. Its product portfolio is centered on hard disk drives (HDDs), including high-capacity drives used in cloud data centers, enterprise environments, surveillance systems, network-attached storage and personal computing.
The company also offers solid-state drives (SSDs), storage systems, external storage products and related services.
Featured Articles Five stocks we like better than Seagate Technology NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Seagate Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagate Technology and related companies with MarketBeat.com's FREE daily email newsletter.
SailPoint představil IdentityIQ 9.0 pro lokální nasazení a nové cloudové funkce Human Fabric, včetně žádostí o přístup využívajících AI a prevence konfliktů oprávnění v reálném čase.
New SailPoint Human Fabric capabilities and SailPoint IdentityIQ 9.0 release deliver security and governance built for enterprise scale, ensuring no customer is left behind in their security evolution | Source: SailPoint Technologies, Inc.
AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Today at its annual flagship conference, Navigate, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced a significant modernization across its entire identity platform. The company unveiled new enterprise-scale capabilities for SailPoint Human Fabric and the release of IdentityIQ 9.0, a major update to its on-premises solution. These updates demonstrate a unified commitment to modernizing identity security for every customer, whether in the cloud, on-premises, or in a hybrid environment.
The announcements address a challenge facing the industry as a whole: most identity governance infrastructure can't keep pace with how enterprises operate today. SailPoint is closing that gap with substantive updates that re-platform core services for scale and strengthen governance, not simple UI refreshes.
Chandra Gnanasambandam, EVP of Product and Chief Technology Officer at SailPoint, said:
"Most vendors ask their customers to choose between a growth story or a stewardship story, but the reality of the modern enterprise is not that simple. Today, we are delivering on both fronts. We are advancing the frontier of cloud identity security with Human Fabric while also demonstrating our commitment to the customers who rely on IdentityIQ for identity security. This is one modernization effort on two fronts, ensuring every customer has a path forward without compromise.”
Governance built for enterprise scale: The SailPoint Human Fabric
SailPoint announced three new major updates for Human Fabric, its cloud-native identity security product, designed to operate at enterprise scale:
Access certifications enhancements: A completely re-platformed certification engine built to handle enterprise-scale access reviews without record limits or data delays. The new engine removes the need for administrators to manually split large campaigns and includes a faster, more intuitive reviewer interface and cryptographic, GxP-compliant sign-off for regulated industries.Proactive Separation of Duties (SoD): Moving beyond after-the-fact alerting, SailPoint’s enhanced SoD engine provides real-time evaluation that proactively blocks toxic access combinations at the moment of request. It uniquely flags conflicts created by other pending requests still in-flight, preventing violations before they occur.Conversational Access Requests: A new AI-powered agent allows users to make access requests in natural language directly from their chat tools. With support for custom forms, employees can provide necessary business justifications and compliance details seamlessly within the chat flow.
No customer left behind: IdentityIQ 9.0
For customers with extensive data residency requirements, strict regulatory constraints, or deeply customized programs, SailPoint is delivering IdentityIQ 9.0. The release provides a parallel modernization path for hybrid and on-premises deployments, centered on three pillars: a stronger governance, including granular, time-based access for roles and entitlements, and a rebuilt technical foundation running on modern application servers, with a refreshed user experience that streamlines access reviews and application definition.
Critically, SailPoint is also offering an automated upgrade tool with the release. This utility scans a customer’s environment and automates much of the manual work required to update, addressing the primary risk that stalls on-premises upgrades and proving that customers can confidently evolve their existing deployments.
Learn more about all the new products announced today at Navigate here.
About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world's leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management's current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.
Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.
More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.
The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint's products that are not currently available remain at SailPoint's sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.
Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275 [email protected]
Průzkum společnosti SailPoint ukázal, že 79 % organizací nasazuje AI agenty, ale pouze 2 % využívají specializované nástroje pro správu jejich identit.
Fifth annual Horizons of Identity Security report reveals a 40x gap between AI adoption and identity security readiness | Source: SailPoint Technologies, Inc.
AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Today from its annual Navigate conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, released its fifth annual Horizons of Identity Security report, revealing that enterprise AI adoption has dramatically outpaced the identity security controls needed to govern it. The study finds that while 79% of organizations are now running AI agents in production, a mere 2% are using identity security tools specifically designed to manage and govern them — a 40-to-1 gap that exposes businesses to significant risk.
This gap is driven by a stark divergence in security maturity between human and non-human identities. While organizations have made impressive strides with human security—nearly halving those at Horizon 1 maturity from 45% in 2022 to just 23% today—the explosion of autonomous AI agents has introduced a new deficit. Agent identity starts from a steep lag, with 54% of organizations currently sitting at Horizon 1. With AI agents already active in production, enterprises do not have the luxury of a five-year runway to catch up; they must compress a five-year human security curve into a one-year agent timeline.
Wendy Wu, Chief Marketing Officer at SailPoint, said:
"Compressing a five-year maturity curve into a single year presents a massive operational challenge, starting with a fundamental awareness gap. Many organizations don't yet realize that they do not have the right tools purpose-built for the scale and velocity of agent and non-human identity security. You cannot bridge this gap by asking human-speed tools to work faster; security must be built for machine speed from the ground up, with discovery, ownership, and access decisions happening in real time rather than on a quarterly review cycle. Enterprises waiting for their agent programs to mature the way their human programs did are going to find out the hard way that they don't have five years."
Key findings:
AI adoption has severely outpaced security controls: AI agents now represent 22% of all non-human accounts, yet 85% of organizations continue to rely on legacy identity tools not designed for agentic identities.Overall maturity remains anchored at foundational levels. Roughly sixty percent of organizations remain in Horizons 1 and 2, while less than 1% have achieved Horizon 5. This lag is overwhelmingly driven by non-human identity deficits: 87% rate their human IAM capabilities as capable or better, while only 43% report mature processes for agentic access.A pronounced awareness gap masks operational vulnerability: 80% of leaders believe the gap in their current tooling is moderate or smaller, yet the operational reality is that only 15% can provision non-human access in real time. Similarly, 57% express confidence in meeting regulatory requirements, while only 43% feel prepared to produce verifiable evidence in an AI-related audit.Foundations remain the primary operational roadblock. Before enterprises can realize dynamic, intent-based security, they must first master baseline hygiene and visibility. Credential lifecycle management, shadow AI discovery, and real-time monitoring are rated as severe operational hurdles across the market.The business value of non-human identity security is immediate and measurable: Mature identity programs deliver significant business velocity. 62% of organizations that have invested in securing non-human identities report measurable productivity gains, and 46% report safer, faster AI deployment. Looking ahead, 76% of leaders expect stronger identity governance to improve their eligibility for — or the terms of — cyber insurance.
The report concludes that the mandate for security leaders is to move from a fragmented, human-centric approach to a unified identity fabric that governs all identity types—human, machine, and AI agent—with continuous, context-aware automation. By advancing from foundational tiers (Horizons 1-2)—where organizations struggle with manual controls and lack basic visibility—to advanced maturity (Horizons 4-5), enterprises gain the real-time visibility and automated policy enforcement needed to secure autonomous agents. This transition pays off well beyond basic compliance; mature organizations are twice as likely to realize significant productivity gains and three times more successful at deploying AI safely, effectively transforming compliance from a reactive audit scramble into a state of automated, continuous assurance. This is the only path to closing the security gap while enabling the full velocity of the autonomous enterprise.
About the report
The 2026 Horizons of Identity Security report is based on a global survey of 340 senior identity, IT, cybersecurity, and risk leaders conducted by SailPoint, evaluating organizations across strategy, operating models, talent, technical confidence, and technical capabilities against a five-tier maturity model ranging from Horizon 1 (No formal program) to Horizon 5 (Ecosystem integrated).
To read the full 2026-2027 “Horizons of Identity Security” report, please visit here.
Check out the livestream of SailPoint CMO Wendy Wu revealing the findings of this year’s Horizons report from SailPoint Navigate.
About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world's leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.
Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275 [email protected]
New York, New York--(Newsfile Corp. - October 6, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has hired Jennifer Charlton, Ph.D., as its Vice President of Fuel Technology.
Dr. Charlton brings nearly two decades of experience in nuclear materials, uranium processing, fuel-cycle technology, and advanced manufacturing to NANO Nuclear. Prior to joining NANO Nuclear, Dr. Charlton held several senior technical and leadership positions at the Y-12 National Security Complex. Notably, she served as Chief Scientist and U.S. Lead for Nuclear Material Verification, leading technical initiatives and providing comprehensive technical expertise across the nuclear fuel cycle, from uranium mining and milling through conversion, enrichment, fuel fabrication, and finished fuel and weapons component operations.
"NANO Nuclear's strategic focus on building capabilities across key areas of the nuclear fuel cycle is an important part of supporting its long-term microreactor deployment strategy," said Jennifer Charlton, Ph.D., Vice President of Fuel Technology of NANO Nuclear Energy. "I'm excited to join the team at this important stage of its growth and leverage my experience leading complex technical initiatives to help advance this strategy and strengthen NANO Nuclear's capabilities across the fuel cycle."
Figure 1 - NANO Nuclear Energy Hires Former Y-12 Leader and Nuclear Fuel Cycle Expert, Jennifer Charlton Ph.D. as its Vice President of Fuel Technology.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/317616_08bb19ec343c59a3_002full.jpg
Dr. Charlton earned a Ph.D. in Chemistry from the University of Tennessee, a Bachelor of Science in Chemistry from the University of North Florida, and an Associate of Arts from Florida State College. Her graduate research encompassed automated radiochemical separations, nanofabrication, surface-enhanced spectroscopy, mass spectrometry, instrumentation development, nuclear forensics, trace-level materials analysis, and materials characterization.
"It is a pleasure to welcome Dr. Charlton to the NANO Nuclear team," said Jay Yu, Founder and Chairman of NANO Nuclear Energy. "Her addition marks another step towards ensuring that we have the right personnel to oversee NANO Nuclear's long-term strategic focus on vertical integration. Her experience within the Y-12 National Security Complex will be invaluable as we look to expand our capabilities across the nuclear fuel cycle."
Dr. Charlton joins a growing list of former senior nuclear leaders and builds on NANO Nuclear's recently announced addition of Marylin Diaz to support the Company's expansion across the nuclear fuel cycle. In her role as Vice President of Fuel Technology, Dr. Charlton will be responsible for evaluating opportunities to expand NANO Nuclear's capabilities across the nuclear fuel cycle and leading the design, engineering, and development of related technologies, with a focus on the uranium conversion, deconversion, and fuel fabrication processes. She will also provide technical expertise to inform strategic decisions regarding NANO Nuclear's broader vertical integration strategy in support of future advanced reactor deployments and nuclear logistics activities.
"As our core, proprietary technology, the KRONOS MMR™ Energy System, continues along its development pathway, we are working to expand across the nuclear fuel cycle to help de-risk the marketplace as well as support the energy sovereignty of the United States," said James Walker, Chief Executive Officer of NANO Nuclear Energy. "Dr. Charlton's appointment is a key step in that effort, and I am delighted to welcome her to the Company. I believe that Dr. Charlton's addition, as well as her experience and knowledge of the inner workings of the fuel cycle will prove to be incredibly important as we continue to put together the building blocks for our next stages of growth."
About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.
Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.
Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.
HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.
NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.
This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "explore," "plans", "aim," "goal," "believes", "potential", "future," "will", "should", "could", "would" or "may" or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements relate to the anticipated benefits of Dr. Charlton joining the Company, as well as the Company's vertical integration and other operational plans and goals. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear's control, as well as the following: (i) risks related to our U.S. Department of Energy ("DOE"), U.S. Nuclear Regulatory Commission ("NRC"), Canadian Nuclear Safety Commission ("CNSC") or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317616
Source: NANO Nuclear Energy Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Descartes Systems Group uvedla platformu Agent Control Plane, která má řídit AI agenty napříč aplikacemi a obchodními partnery při zachování zákaznických oprávnění a lidského dohledu.
CHICAGO and LONDON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, introduced the Descartes Agent Control Plane at its Innovation Forum in Chicago, which this year brings together a record number of customers, speakers and sponsors to explore innovation in supply chain and logistics technology. Built on the Descartes Global Logistics Network™ (Descartes GLN™), the Agent Control Plane is designed to build trust in AI agents by coordinating them across applications and trading partners to execute multi-step workflows within defined guardrails, policies and human oversight.
“Even with connected systems, supply chain teams devote significant time to interpreting updates from emails, messages and portals, rekeying information and coordinating next steps to move orders forward,” said Ken Wood, Executive Vice President, Product Management at Descartes. “The Agent Control Plane brings our logistics capabilities together so AI agents can take on more of that work across applications, conversations and company boundaries; keep it moving as replies and approvals arrive; and act on events as they occur within permissions and approval points defined by customers. It’s an important step in our AI strategy, helping customers build on the Descartes solutions and AI platforms they already use and apply AI to the operational outcomes that matter, from reducing manual follow-up to keeping customer commitments on track.”
The Agent Control Plane combines the operationally ready data and connectivity of the Descartes GLN with capabilities from Descartes solutions to help AI agents coordinate work across applications and trading partners, and to make Descartes agents available within the AI platforms customers already use. The GLN supplies the logistics context to connect changes in one part of a shipment’s journey with actions needed elsewhere, while the Agent Control Plane applies customer-defined permissions and approvals and maintains a traceable record of agent actions. Together, they help reduce manual handoffs, accelerate responses to changing conditions and give teams more time to focus on exceptions and customer relationships.
“We’re pleased to welcome such a strong community of customers, sponsors and speakers to this year’s Innovation Forum,” said Edward J. Ryan, CEO at Descartes. “Record participation reflects the value of bringing this community together to share experiences, learn from one another and explore new possibilities. The conversations we have here help us understand our customers’ priorities and shape how we continue to innovate in support of their success.”
Bringing together 1,000+ attendees and 200+ speakers this year, the three-day Innovation Forum features sessions across fleet performance management, transportation management, global trade intelligence, logistics service providers and ecommerce operations. Industry and customer presentations, discussions with Descartes product specialists and hands-on demonstrations at the Technology Fair give attendees opportunities to explore practical ways to improve operations and gain more value from their technology investments.
To learn more about event speakers, sessions and sponsors, visit www.descartes.com/innovation-forum.
About Descartes
Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.
Global Media Contact
Cara Strohack
Tel: 226-750-8050 [email protected]
This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ logistics and supply chain solution offerings and potential benefits derived therefrom; the innovations Descartes intends to present at its Innovation Forum in Chicago; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, Descartes undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
Společnost Galectin Therapeutics předložila FDA protokol registrační studie fáze 3 s belapectinem zaměřené na prevenci progrese cirhózy MASH a portální hypertenze.
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.
In addition, the Company also announced today that it has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA).
“We are excited to have our ANTICIPATE-NASH analysis selected for oral presentation and the recognition of our Baveno and ELF analysis as a Poster of Distinction. These selections reflect not only the depth of the NAVIGATE trial datasets but also underscores the importance of non-invasive assessments in diagnosis of portal hypertension in patients with MASH cirrhosis who are at increased risk of developing serious complications such as varices. This represents the fourth consecutive major liver meeting where the Company has been selected for an oral presentation, and I want to thank our entire team led by Dr. Khurram Jamil, our Chief Medical Officer, for their efforts in this achievement. We have also submitted the registrational Phase 3 protocol, an important step forward in the advancement of our belapectin program for patients who today have no approved treatment options,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.
Presentation Details
Oral Presentation
Title: ANTICIPATE-NASH Risk Stratification Predicts Variceal Development in Compensated MASH Cirrhosis: Results from the NAVIGATE Trial
Publication Number: 0253
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 8, 2026, 9:15 am - 9:30 am MST
Poster Presentations
Poster of Distinction:
Title: Baseline Baveno Portal Hypertension and ELF Risk Stratification Predict Variceal Development in Compensated MASH Cirrhosis: Findings from the NAVIGATE Trial
Session: MASLD/MASH - Therapeutics: New Agents and Approved/Available Agents
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 7, 2026 at 12:00 pm - 1:00 pm MST
Title: Correlation of Baveno VII and ANTICIPATE-NASH Noninvasive Models with HVPG in Patients with MASH Cirrhosis: Findings from a Phase 2b Belapectin Trial
Session: Portal Hypertension and Other Complications of Cirrhosis
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 5, 2026 at 12:00 pm - 1:00 pm MST
The presentations will be available for viewing by AASLD attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186 [email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
Ofcom vyšetřuje společnost Meta kvůli možnému porušení britského zákona o online bezpečnosti v souvislosti se spuštěním funkce Instagram Instants a možným nedostatečným posouzením rizik nelegálního obsahu či přístupu dětí.
Mark Zuckerberg’s Meta is under investigation for a potential breach of the UK’s digital safety laws after launching a Snapchat-style feature on Instagram.
The UK’s communications watchdog, Ofcom, is investigating whether the $1.9tn (£1.4tn) company infringed the Online Safety Act (OSA) by failing to carry out adequate checks on whether its Instagram Instants product could show illegal content or be accessed by children.
Social media companies are required to carry out risk assessments before making significant changes to their service’s design or operation. Breaching the OSA carries a range of potential actions, from a formal warning to a fine of up to 10% of global revenue.
George Lusty, the director of enforcement at Ofcom, said risk assessments were a vital step in keeping tech platforms safe for users. “You wouldn’t launch a new car without testing it properly, and it’s the same for online services,” he said. “Safety by design must be built in, not bolted on, and today’s investigation shows we’ll take action where we have concerns that providers are failing to comply.”
Screenshots of Instagram Instants. Photograph: Meta NewsroomInstagram’s Instants feature allows users to send images that disappear after viewing. The company said it had conducted a risk analysis of Instants and talked to Ofcom on a number of occasions before launching it. It said the feature carried protections such as blocking forwarding and included all the safeguards under its teen account settings, the default mode for under-18s on Instagram, Facebook and Messenger.
“We will of course cooperate with Ofcom during this investigation,” a Meta spokesperson said.
The Molly Rose Foundation, a charity established by the family of Molly Russell, a teenager who took her own life after viewing harmful content on Instagram, said it was crucial that Meta was “held to account for their failures under the Online Safety Act”.
Ofcom is already investigating whether Meta breached the law by failing to comply with a request for information related to its WhatsApp platform.
Zuckerberg’s company is challenging Ofcom in court over the OSA. It is suing the regulator in the high court over how it charges tech firms fees to cover its operating costs, and in a further case it is challenging Ofcom placing it in a new category under the act that subjects it to additional duties.
Meta has also joined TikTok and Elon Musk’s X in a court challenge over the amount information Ofcom is demanding they provide under the UK’s new online safety regime.
Federální soud v New Yorku připustil k projednání žalobu proti Googlu ve výši přibližně 3,2 mld. USD; případná přiznaná náhrada škody by se podle antimonopolních předpisů automaticky ztrojnásobila.
A federal judge just cleared billions in ad-tech damages claims against Google to proceed to trial, where antitrust law would automatically multiply whatever a jury awards. But the real threat to Alphabet shareholders may not be this case at all.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
On September 30, 2026, a federal judge in New York signed an 88-page opinion. The opinion denied most of Google’s motions to dismiss advertising-technology damages claims. That leaves about $3.2 billion in claims for a jury to hear.
The ruling was first reported on October 1, 2026. Alphabet (NASDAQ:GOOG | GOOG Price Prediction, NASDAQ:GOOGL) shares closed the most recent session at $346.47, up 0.86%.
The dollar figure is what plaintiffs seek, and US antitrust law automatically triples whatever a jury awards. No trial date has been set.
Shareholders face a key question. Can a bill this size hurt a company worth $4.2 trillion, or is the bigger risk the copycat claims that may follow?
What the Court Allowed and What It Dismissed Plaintiffs claim about $1.72 billion for a certified class of about 5,000 publishers. They also claim about $900 million for USA Today Co. (NYSE:TDAY), formerly Gannett, and about $600 million for the Daily Mail.
USA Today Co.’s chief legal counsel spoke about the ruling. He said it lets the company go after “$1 billion in worldwide damages (before trebling under the antitrust laws)”. That $1 billion figure is the company’s own framing. The opinion shows the smaller amount.
Google also won some ground. The court dismissed claims from publishers who used other advertising tools, along with a separate $479 million claim. Google said it will “defend the rest in court.”
No damages have been awarded. If a jury granted the full amount, trebling (the automatic tripling) would push it to a theoretical $9.6 billion.
How Big $9.6 Billion Is Against Alphabet Alphabet earned $40.77 billion in operating income in the second quarter of 2026 alone, on revenue of $119.80 billion. Even the tripled maximum is smaller than one quarter of operating profit.
Alphabet absorbed a $3.5 billion European Commission competition fine in its third-quarter 2025 results, which shows the company has paid penalties of this scale before.
Cash flow is where a large payment would matter. Free cash flow was -$5.855 billion in the second quarter because capital spending reached $44.924 billion.
Why Publisher Claims Are Harder to Escape A 2025 ruling in Virginia found that Google illegally monopolized parts of the ad-tech market. That finding carries over to New York, which is why the damages phase is under way. On September 2, 2026, a judge turned down a request to break up the ad business and ordered operational changes instead.
Harm from search antitrust spreads across consumers and is hard to price, but publishers are direct customers with measurable lost revenue, so a court can calculate their damages.
That makes this case a model. Other publishers can copy the structure of one large class plus two big individual plaintiffs. Future claims may matter more than this case.
What the Lawsuit Means for Alphabet’s Valuation The market’s calm looks correct. The stock trades at 23x forward earnings, and analysts hold 13 strong buys and 43 buys, with 0 sells.
For now, the case is a cost Alphabet can absorb. It would become a reason to rethink the stock only if copycat suits multiplied the exposure while free cash flow stayed negative. Then legal payments would be stacked on long-term debt that has already grown to $98.2 billion.
The business case outweighs the litigation. Google Cloud grew 82% in the second quarter, and that growth matters far more to the valuation than this litigation does.
Watch for a trial date on the schedule and the legal reserve reported with third-quarter results expected October 28, 2026. Also watch whether the stock holds its 200-day moving average of $338.92.
Contact [email protected] for any questions or corrections.
Microsoft ve fiskálním 4. čtvrtletí zvýšil tržby o 17,8 % na 90,0 mld. USD; Azure vzrostl o 43 % a objem nasmlouvaných komerčních zakázek o 84 % na 678 mld. USD.
Microsoft has beaten earnings estimates six quarters running while its stock sits roughly where it did a year ago, and Jim Cramer thinks he knows exactly why the market is finally starting to catch on.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Microsoft (NASDAQ:MSFT | MSFT Price Prediction) shares were at $528.25 in premarket trading on Tuesday, October 6, 2026, up fractionally from the previous close. The stock is 3.5% higher over the past week and 6.3% over the past month, but that puts it in the same neighborhood as a year ago.
That flat year came while Microsoft beat earnings estimates in six consecutive quarters. Shares were at $517.85 when fiscal Q1 2026 results were filed in October 2025, $451.01 at the January filing (when the stock fell despite a beat), and $395.50 when the fiscal Q4 report came out on July 29, 2026. On Monday’s Mad Money, Jim Cramer argued that the market has been slow to see something enterprises already decided.
Cramer’s Boardroom Test Points to Microsoft Cramer framed the enterprise AI decision as one an executive makes in front of directors: “If you’re going to be making a presentation to a board meeting right now after what’s happened about which AI platform you should use, you would say, I don’t know. Let’s just turn it over to Microsoft.”
His case rests on institutional trust and governance. He leaves aside the question of which model does best. “Microsoft is already a trusted partner of the enterprise, with nothing erratic about its leaders,” he said, adding that “boards don’t like surprises or erratic behavior, and Microsoft has good governance.” He also said he was “shocked” to see Microsoft leapfrogging rivals in what he called net future usage intent. He did not say where that finding came from.
What Microsoft Has Actually Reported Trust only matters to shareholders if it shows up as revenue. Jim Cramer said Copilot has more than 30 million paid users. Microsoft’s own July disclosure counted more than 30 million paid Microsoft 365 Copilot seats, which is a different unit. A single customer can buy a huge number of seats: HSBC (NYSE:HSBC), for example, committed to 200,000 seats.
In fiscal Q4 results filed with the SEC, revenue reached $90.0 billion, up 17.8%, beating the $87.63 billion consensus. Azure and other cloud services grew 43%, and Azure passed $100 billion in full-year revenue for the first time. Per-share earnings of $4.74 topped the $4.24 estimate, though that figure includes a $3.2 billion gain from Anthropic.
The backlog data matches Cramer’s thesis best. Commercial remaining performance obligations rose 84% to $678 billion, and grew 25% excluding OpenAI. Nearly 90% of annual Microsoft Cloud revenue came from customers outside frontier model companies.
Why Shareholders Waited The spending side of the story kept investors cautious. Fiscal 2026 capital expenditure reached $115.95 billion, up 79.6%, while free cash flow fell 6.5% to $66.99 billion. Management now expects calendar 2026 capex of about $175 billion and says fiscal 2027 spending will grow again. (All that money has to be spent on power, cooling, and networking gear supplied by someone, which is the whole basis of a free report we put together on seven AI infrastructure names that aren’t chipmakers.)
Jim Cramer said Azure “might grow as fast as 50%.” The company’s own guidance calls for fiscal Q1 Azure growth of approximately 45% in constant currency. On the July call, management said, “demand continues to exceed available supply” and warned that growth can vary by quarter depending on capacity, timing, and contract mix. More detail is posted on Microsoft’s investor relations site.
One Azure Number Will Settle the Debate Microsoft’s next report is expected around October 27, 2026, though the company has not confirmed the date. If Azure grows at or above the 45% constant-currency guidance and backlog outside OpenAI keeps expanding, the recent rally has a genuine business foundation and Cramer’s trust argument is translating into revenue. If Azure falls short of guidance while capex keeps rising, the market’s year of skepticism was right.
Contact [email protected] for any questions or corrections.
Stifel expects a beat-and-raise quarter, though AMD's valuation leaves investors focused on the MI450 ramp and longer-term AI growth. Summary
Stifel raised its AMD price target to $700 from $635 and maintained a Buy rating.
Stifel set a higher price objective for Advanced Micro Devices Inc. (AMD, Financials), a semiconductor business that competes in server CPUs and AI accelerators, as anticipation grows for yet another successful quarter.
While keeping a buy rating, analyst Ruben Roy increased his objective from $635 to $700. He anticipates that AMD will improve its forecast and produce better-than-expected third-quarter earnings. For investors, however, the quarter itself might not be the main problem.
Roy anticipates that the focus will be on the management's 2027 data-center projection, the timing of MI450 revenue, and the fourth-quarter guidance. In the past, AMD predicted that data-center revenue would rise by around 60% annually, with AI data-center revenue growing by about 80%.
While server-build capacity and DRAM supply continue to be limitations, Stifel also views EPYC server chips as a possible source of short-term gain.
There are already high expectations. Currently trading at nearly 29 times Stifel's projected 2028 earnings, AMD shares have increased by about 195% this year. The company's updated 2028 adjusted EPS projection is multiplied 32 times by its $700 objective.
The investing argument is moved beyond a single earnings beat by this price. According to Stifel, the optimistic argument rests more and more on AI data-center income ultimately surpassing management's current "tens of billions" framework.
AMD's third-quarter report, especially the fourth-quarter outlook and any more information on MI450 and the 2027 data-center ramp, will be the next trigger.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
The personal AI agent boom is giving Advanced Micro Devices and Intel new life after the companies spent years watching Nvidia and its GPUs dominate the artificial intelligence market.
The central processing unit, or CPU, was once the primary workhorse of a computer server before Nvidia's graphics processing units took center stage with the launch of ChatGPT and the start of the generative AI era. Now CPUs are back, lifting the fortunes of market leaders AMD and Intel, whose chips specialize in powering long-running agents that can work for hours on their own.
Last week OpenAI released its AI agent Dots, following the lead of Meta, which debuted Muse in early September. Muse caught on so quickly that it topped the Apple App Store in less than two weeks. Well before that, AMD and Intel were already huge winners in the stock market this year due largely to surging demand for CPUs, but they've picked up steam in the past month, jumping 32% and 21%, respectively, beating all of tech's megacaps.
AMD's growing strength in both CPUs and GPUs has pushed the company into the trillion-dollar market cap club.
"As more agents are created and developed, and more people start to use them for more tasks, it's going to start to shift the workload away from GPUs and onto CPUs," said Ryan Shrout, president of Signal65, which consults on AI hardware and costs.
Users learned about the power behind the new agents by asking them. Muse tells users that it runs on an AMD-powered computer, while Dots said it runs on a virtual computer powered by AMD's EPYC-branded CPU.
A Meta spokesperson told CNBC that the company designed its system to use whatever kind of CPU is available.
"We take a diverse approach to our hardware and are largely CPU-agnostic by design, which gives us the most flexibility in acquiring capacity," the Meta spokesperson said in a statement.
OpenAI similarly uses multiple CPU providers, meaning AMD isn't the only game in town.
Most servers at hyperscalers — Amazon, Google, Meta and Microsoft — use CPUs made by Intel or AMD. But nearly every major cloud provider is also developing custom chips of their own, typically based on Arm technology. Arm announced its own CPU for agents in March, with Meta as the debut customer, and its stock price has more than doubled since.
watch now
Earlier this year, Nvidia released Vera — a fully redesigned central processor — along with an entire rack filled only with the CPUs. The chip giant says it built the new Vera CPUs specifically for agents and expects CPUs to be a $200 billion market by 2030.
But it's one part of the chip industry where Nvidia isn't currently the favorite, analysts say.
"It's just a new product and they're going to be competing against a lot of different players," Jordan Klein, an analyst at Mizuho Securities, said in an interview, adding that he believes AMD currently has the "best product."
CPUs are driving a healthy portion of AMD's growth. Revenue in the company's data center business more than doubled to $6.7 billion in the quarter ended in June, accounting for almost 60% of total sales.
"The conversation has changed quite a bit over the last eight to 10 months in terms of agentic usage," said Dan McNamara, AMD's senior vice president and general manager of compute and enterprise AI. McNamara added that CPU sales are going to "really ramp."
GPUs think, CPUs doMuse, Dots and even coding software like OpenAI's Codex use AI models to plan tasks that can run autonomously. The agents need their own computer that can run for hours or even days in the background, explained Futurum Group CEO Daniel Newman.
GPUs are still needed for inference, or processing an AI model, but an agent also needs a CPU.
"CPUs are actually performing the workflows while GPUs are doing the thinking," Newman said.
Meta and OpenAI use virtual machines, which partition a server into several lighter virtual computers, so one server can support scores of users.
Some AMD EPYC processors have up to 192 CPU cores. According to benchmarks and the agents themselves, Muse's virtual computer uses two cores and Dots uses nine.
CPUs are less expensive than GPUs.
Benchmarks and queries show Dots using an AMD EPYC 9V74 CPU, which is available from resellers for under $3,000. The EPYC 9D25 reportedly used by Meta for Muse costs even less on the secondary market. Nvidia GPUs can cost more than 10 times that for a single chip, and they're usually sold in clusters of hundreds or thousands of chips.
Investors are watching how Meta plans to serve Muse users, after downloads surpassed 5 million since last month's launch, according to Sensor Tower. Morgan Stanley estimates Muse's serving costs at $3 to $130 per month, with an average of $37 per user, depending on inference usage.
The firm says Meta's agent could account for 20% of AMD's 2026 chip sales.
There's a lot of money to be made in CPUs, and forecasts for the segment's growth are accelerating.
Futurum estimates $118 billion in total CPU sales in 2027, almost double the firm's previous forecast in May.
In July, AMD predicted the entire CPU market would hit $220 billion in sales in 2030, up from a previous 2025 forecast of $60 billion. AMD said in July that it expects to take more than half of the market.
AMD currently commands about 46% of the market for x86 CPU units, Mercury Research said in August. Intel is also seeing a surge in demand.
But AMD has a foothold with hyperscalers, which is where many of the virtual machines for agents will be deployed. It also has the benefit of using an x86 architecture for its chips, allowing agents to use older software without worrying about compatibility issues.
"AMD is probably getting the most of this because they have the largest market share and the cloud hyperscaler world for CPUs," Klein said, adding that he "wouldn't rule Nvidia out."
"If you are a company that can supply both types of chips, you're in the best position," Klein said.
WATCH: Helios is AMD's first AI system to rival Nvidia Vera Rubin — we got an exclusive, first look
Boeing získal od amerického námořnictva kontrakt v hodnotě zhruba 20 mld. USD na vývoj palubního stíhacího letounu a zakázku od Lockheed Martin v hodnotě až 14,7 mld. USD na naváděcí hlavice pro střely Patriot.
Boeing just landed a Navy fighter contract, a multibillion-dollar missile deal, and an FAA all-clear in a single week, yet analysts still see the stock trading at a 40-plus percent discount to where they think it belongs.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Four pieces of good news reached Boeing (NYSE:BA | BA Price Prediction) in seven days, yet the stock trades at $192.74 against an average analyst price target of $273.42. That leaves an implied upside of about 41.9%.
A gap above 40% is unusual for a company valued near $152.3 billion. Of 28 analysts, 6 rate the stock a Strong Buy, 18 rate it a Buy, and 4 rate it a Hold, with no Sells.
The week brought a Navy fighter selection, an approved engineering labor contract, an FAA finding on a MAX software bug, and a large missile-seeker order. The shares gained 4.52% over the week but remain down 11.24% this year, while the S&P 500 is up 13.62%.
Boeing reports third-quarter results before the market opens on October 27, 2026, a date it confirmed on September 30, 2026. Until then, the market is pricing this news as promises that take years to become cash. I think that discount is partly earned.
Why a $20 Billion Fighter Award Pays Slowly On September 29, 2026, the Navy selected Boeing to build its next carrier-based fighter under a development contract worth about $20 billion. Winning a next-generation fighter usually brings decades of production, upgrade, and maintenance work.
One analyst firm cut its Northrop Grumman (NYSE:NOC) target to $525 from $640 after the award, evidence that the contract carries real economic weight. But the money covers development, and production revenue is years away. A protest by the losing bidder would likely move the calendar by months without changing the long-term economics, unless the award were reversed.
Ceilings, Obligations and Revenue Are Different Numbers On October 5, 2026, Lockheed Martin (NYSE:LMT) awarded Boeing a contract worth up to about $14.7 billion over seven years to raise Patriot interceptor seeker output toward 2,000 a year from about 600.
That figure is a ceiling, the most the customer can spend. Obligated value is money committed through actual orders, and revenue is what Boeing records as it ships seekers. Congress has not yet appropriated the funds, and ceilings are routinely underspent, so treat the headline figure as an upper bound.
Only the FAA Finding Touches What Drives the Stock Boeing’s valuation runs on commercial deliveries and free cash flow. Last quarter it delivered 171 airplanes and generated $631 million in free cash flow, and management guided to $1 billion to $3 billion for the year.
On October 2, 2026, an FAA review board found the MAX flight-computer bug is not a safety issue. The bug had threatened to delay certification of the stretched MAX, and because airlines pay most of a jet’s price at delivery, a certification slip leaves finished planes parked and cash unpaid.
The contract covering about 17,000 engineering and technical workers removes strike risk at a company whose troubles have come from execution. However, its immediate 10% raise adds cost to a commercial unit that posted a negative 2.7% operating margin last quarter.
Boeing Carries the Widest Gap Among Defense Peers Some defense peers have sold off too. Northrop trades at $476.11, down 16.5% this year, against a consensus target of $639.23 that implies about 34.3% upside, though that average may precede the post-award cut. Analysts split 4 Strong Buy, 10 Buy and 10 Hold.
Lockheed is up 6.66% this year at $506.54, with a $636.74 target implying about 25.7% upside. Its ratings tilt cautious, with 2 Strong Buy, 5 Buy, 13 Hold, and 1 Sell. Boeing shows the largest implied upside of the three, although targets carry no guarantee and its wider spread reflects heavier execution risk.
What Would Confirm or Break the Boeing Turnaround At this price, Boeing trades closer to its 52-week low of $176.77 than its high of $254.35. The bull case needs the 737 ramp toward 47 a month to hold, certification of the 737-7 and 737-10, and positive free cash flow every quarter, starting with management’s call for third-quarter cash in the low hundreds of millions.
It becomes a value trap if the October 27 report shows cash flow turning negative, if stretched-MAX certification slips again, or if fixed-price defense programs take more charges as last quarter’s $280 million VC-25B hit.
Northrop offers defense exposure without commercial-aircraft risk at about 15 times trailing earnings. Boeing’s gap to its consensus target is the widest of the three, and the October 27 report will show whether the turnaround clears it.
Contact [email protected] for any questions or corrections.
BNP Paribas zvýšila cílovou cenu akcií Nvidia z 285 USD na 345 USD a očekává, že firma si udrží nejméně 75% podíl na trhu s výpočetní technikou pro AI.
BNP Paribas Sees Nvidia Holding 75%+ of AI Market and Raises Target Summary
BNP Paribas raised Nvidia’s price target to $345 from $285, implying about 47% upside as it expects continued strength in AI computing
BNP Paribas lifted its Nvidia NVDA price target to $345 from $285, maintaining an Outperform rating as it sees the chipmaker benefiting from the shift toward more demanding AI inference workloads.
The revised target represents about 47% upside from Nvidia's Oct. 2 closing level of $234. BNP Paribas expects the company to retain at least three-fourths of the AI computing market by dollar value, despite gains by AMD and custom-designed accelerators.
The brokerage's view extends beyond Nvidia's graphics processors. It sees the upcoming Vera Rubin platform, which combines computing, networking and other components, as important for agentic AI systems handling more complex tasks.
Nvidia's software and networking capabilities may also help it defend its position as AI infrastructure becomes more integrated. BNP Paribas expects server CPUs and networking to add to the company's growth opportunities.
The brokerage also forecasts gross margins above 70% despite competition. Its valuation framework applies a 15-times multiple to estimated calendar 2028 earnings, alongside cash, to support the new target.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Edible Garden získala nový program dodávek čerstvých bylinek pro Walmart na období od amerického Dne díkůvzdání do Nového roku, nad rámec stávající distribuce.
BELVIDERE, NJ, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded a new fresh herb program with Walmart for the upcoming Thanksgiving through New Year holiday season.
The new holiday program represents incremental business in addition to Edible Garden’s significant existing Walmart distribution and three recently awarded Walmart distribution centers, further expanding the Company’s relationship with one of the world’s largest retailers. Together, these awards strengthen Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast, strategically important markets where the Company believes the combination of Walmart’s substantial retail presence and Edible Garden’s growing fresh herb platform creates a meaningful opportunity to capture additional market share.
The holiday program is designed to meet increased consumer demand during one of the most important selling periods of the year for fresh herbs, as holiday cooking typically drives demand for many of Edible Garden’s core offerings, including rosemary, sage, thyme, parsley, and poultry-blend herbs. Edible Garden is working closely with Walmart on the holiday program across product assortment, production planning, packaging, merchandising, logistics, and replenishment, and preparations for the season are already underway.
To support the new program and the Company’s growing Walmart distribution footprint, Edible Garden plans to leverage its vertically integrated production facilities, strategically located contract grower network, advanced demand-planning capabilities, and proprietary GreenThumb 2.0 technology. Together, these capabilities are designed to provide the flexibility and dependable fulfillment required during periods of elevated demand.
“This award is particularly significant because it represents new business layered onto our already substantial Walmart distribution and follows three recent distribution center wins,” said Jim Kras, Chief Executive Officer of Edible Garden. “Collectively, these programs are strengthening Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast and expanding our participation in some of Walmart’s most important markets. We believe that growing geographic alignment creates an opportunity for both Walmart and Edible Garden to capture additional fresh herb market share while providing consumers with fresher, locally sourced products.
“The Thanksgiving-through-New Year period is one of the most demanding periods of the fresh herb calendar, and our industry-leading fulfillment rate demonstrates our ability to execute at scale. We believe Walmart’s continued expansion of our programs validates the investments we have made in production, distribution, and GreenThumb technology, while deepening our relationship with Walmart and further establishing Edible Garden as a trusted, scalable supply-chain partner to major retailers.”
Edible Garden’s GreenThumb 2.0 platform, together with its network of Company-operated facilities and strategically located contract growers, is designed to more closely align production with anticipated retail demand. This data-driven, localized approach supports the Company’s Zero-Waste Inspired® strategy by helping maintain product freshness and availability while reducing food miles, excess inventory, and shrink throughout the supply chain.
Key Performance Indicator
This press release contains reference to the Company’s fulfillment rate, which is a key performance metric management uses to analyze and measure the Company’s financial performance and results of operation. Management uses fulfillment rate as a measure of current and future business and financial performance, and it may not be comparable with measures provided by other companies. The Company defines fulfillment rate as the percentage of orders filled in full, relative to the total number of orders received during the period.
ABOUT EDIBLE GARDEN®
Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.
Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).
The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way® and Vitamin Whey®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.
Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Walmart, the expected benefits of the Company’s recent Walmart distribution center awards, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Walmart and other major retailers, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Here's the simple math first. Starbucks (SBUX -0.30%) pays an annual dividend of $2.48 per share and recently traded at around $95 per share.A $10,000 investment buys roughly 105 shares at that price, and that payout works out to about $260 a year in dividend income, paid whether the stock goes up, down, or sideways that year.
It won't replace a paycheck, but it's a useful way to picture what owning this stock actually pays an investor in cash, separate from whatever the share price does on any given day.
Image source: Getty Images.
Starbucks' turnaround is finally showing up in the numbers Starbucks spent the past two years working through what Chief Executive Officer Brian Niccol branded the "Back to Starbucks" plan, aimed at fixing slow service, inconsistent stores, and an overly complicated menu. On the plan's two-year anniversary in September, Niccol declared the momentum was finally real, and the numbers backed him up.
Global comparable sales rose 7.9%, with North American sales up 8.1%, and customer visits increased alongside that. It was Starbucks's first quarter of positive global comparable sales in seven quarters.
Management also approved the next phase of its store renovation push, part of a roughly $1 billion plan to refresh up to 9,000 cafes, with more than 1,000 stores already updated and a target of 1,500-plus by year-end, according to SIlive.com. At the same time, the company closed about 250 underperforming North American locations, roughly 1% of its footprint, that weren't meeting its bar for either customer experience or financial performance.
Fixing stores a company already has and being willing to close the ones that don't work is a slower and less flashy strategy than simply opening new locations as quickly as possible. But it's also the kind of discipline that tends to support a durable, growing dividend over the following decade rather than a one-quarter headline.
Premium Feature
Moneyball Superscore
67/100
Today's Change
(
-0.30
%) $
-0.28
Current Price
$
94.43
Restructuring in China frees up cash without giving up the upside Starbucks also fundamentally changed how it operates in China this year, in a way that lowers its risk without walking away from the market's long-term size. The company sold a 60% stake in its roughly 8,000 cafes in China to Boyu Capital for $4 billion, while keeping a 40% ownership interest and continuing to collect licensing fees on use of the Starbucks brand there, according to the AP.
Instead of directly funding and operating thousands of stores in a market where local Chinese coffee chains have been aggressively undercutting it on price, Starbucks now gets paid through its retained stake and brand royalties, while a local partner handles the capital-intensive work of running the stores.
Starbucks has said it now values its China business at more than $13 billion, including the retained stake and ongoing fee stream, and the new joint venture has set a long-term goal of growing to as many as 20,000 locations, according to CNBC. That's a more capital-light way for Starbucks to keep participating in China's growth, with far less of its own cash tied up getting there, and with a partner who understands the local competitive landscape better than a U.S. head office ever could.
How does this add up to a long-term bullish case? Put the three pieces together: a turnaround that's now showing up in actual customer visits, a leaner and less capital-intensive approach to its largest international growth market, and a dividend that has grown for 15 consecutive years, historically at a pace of around 17.5% annually. According to Tikr.com, the stock is expected to continue climbing toward roughly $3.11 per share by fiscal 2030, a meaningful jump from today's $2.48.
A company that is fixing its core stores, closing the ones that don't work, de-risking its largest growth market, and still finding room to raise its dividend every year is exactly the kind of setup long-term investors should want to own through the next several years.
Akcie PayPal (PYPL) se po stažení nabídky společnostmi Stripe a Advent International pohybují do strany; technický vzorec ostrovního zvratu naznačuje možný odraz před výsledky za třetí čtvrtletí.
PayPal stock has remained in a narrow range since September as investors wait for the next move after Stripe and Advent International decided to abandon its buyout. PYPL was trading at $54.41 on Monday, lower than the August high of $62.45. It has formed an island reversal pattern, pointing to a rebound as its third-quarter earnings report loom.
PYPL stock has moved sideways in the past few weeks as investors reacted to the decision by Stripe and Advent decided to abandon their takeover bid. According to Bloomberg, PayPal’s management saw the takeover bid as being highly inadequate. They believe that the company can achieve a better valuation if its turnaround measures work.
PayPal has then reacted to reports that other bidders may be interested in PayPal. Besides, it is one of the most popular companies in the fintech industry. It is also a highly undervalued company with a forward price-to-earnings ratio of 9.80, lower than the sector median of 11. It is also much lower than the five-year average of 16.
A potential acquirer has several ways of boosting shareholder value. For example, PayPal can opt to spin off the highly valuable Venmo product into a separately traded company. It may also decide to sell its non-core assets and cut costs.
PayPal's ongoing PayPal’s weakness is mostly because its growth has stalled following the surge that happened during the pandemic.
Its most recent results showed that the number of PayPal accounts remained flat at 439 million, with the number of active accounts rising by just 1% to 228 million. PayPal’s number of payment transactions rose by 8%, while the number of transactions per active account rose by 3%.
Venmo’s transaction growth continued as it experienced the second consecutive quarter of mid-teens growth.
Analysts expect the company’s revenue growth to remain under pressure for a while. The average estimate among analysts is that its annual revenue will grow by 4.76% this year and 4.2% next year. Its earnings-per-share is also expected to remain under pressure.
Most analysts have a neutral outlook for the company, with the average estimate being $56, a few points about where it is today. 34 analysts have a hold rating, while 9 and 4 have a buy and sell rating, respectively.
PayPal stock chart | Source: TradingView
The daily chart shows that the PYPL stock has struggled in the past few months. It formed a big down-gap in February after releasing weak earnings. It also formed another down-gap in April and an up-gap in July after Stripe and Advent made their bid.
The stock then made a big down-gap in August after the two companies walked away. A closer look shows that it has formed an island reversal pattern, which happens when an asset makes a gap and then consolidates. It has remained above the 100-day Exponential Moving Average (EMA).
Therefore, the stock will likely rebound ahead of its earnings. If this happens, it may rebound to the next key resistance at $62.45, its highest point in August.
Internet, Everywhere, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Shopify Inc. (NASDAQ, TSX: SHOP) plans to announce financial results for the quarter ended September 30, 2026 before markets open on Tuesday, November 3, 2026.
Shopify’s management team will host a conference call to discuss third-quarter results at 8:30 a.m. ET on Tuesday, November 3, 2026. The conference call will be available via webcast on the Investor Relations section of Shopify’s website at https://www.shopify.com/investors/events.
An archived replay of the webcast will be available following the conclusion of the call.
About Shopify
Shopify provides essential internet infrastructure for commerce. Shopify’s all-in-one platform makes it easier to start, run, and grow a business, powering sales online, in store, and everywhere in between. Millions of businesses in 175+ countries use Shopify—from entrepreneurs to brands like Aldo, BarkBox, Carrier, Meta, Vuori, SKIMS, and Supreme.
SAP zahájil nasazování rozhraní Joule Work u zákazníků pro práci s AI napříč daty SAP i daty třetích stran. U svých 110 000 zaměstnanců firma uvádí 20% nárůst produktivity ve financích, HR a nákupu.
Joule Work, Joule Assistants and SAP Business AI Platform help organizations turn business AI into trusted outcomes across every core function.
, /PRNewswire/ -- SAP SE (NYSE: SAP) today showcased the Autonomous Enterprise in action at SAP Connect, demonstrating how Joule Work and Joule Assistants generate value for customers across every line of business.
"This is a breakthrough moment for business AI," said Christian Klein, CEO of SAP SE. "The Autonomous Enterprise has arrived. With Joule and SAP Autonomous Suite, built on SAP Business AI Platform, we're helping organizations like Novartis, Morgan Foods, Nestlé and PwC connect intelligence across every function to deliver trusted business outcomes."
At SAP Connect, these customers shared how the Autonomous Enterprise is already driving measurable value across their businesses.
"We've co-developed and recently launched a pilot of SAP's Joule Sourcing Assistant," said Christoph Buerki, Head of Procurement, Novartis. "Our vision is for AI agents to handle the manual heavy lifting, enabling sourcing professionals to focus on strategy, supplier engagement and value creation." "At Morgan Foods, we're already putting the pieces in place for agentic adoption, especially through our technical foundation. The biggest shift will be moving from reactive to predictive, where agents can connect demand signals, inventory levels and supplier status faster than ever before," said Steve Hankins, Chief Financial Officer, Morgan Foods, "Our superpower will come from people on top of agents. Our approximately ~1,000 employees are what make our supply chains work – the technology helps make them even better." "Our SAP S/4HANA transformation across 140 countries is creating a connected digital core with consistent processes, trusted data and greater visibility across markets and functions. With that foundation, Joule and the Accounts Receivable Assistant can automatically prioritize collections work based on risk and business context, recommend the next best action and help our finance teams respond faster to change," said Luca Dell'Orletta, Global Head IT Innovation & Enterprise Architecture, Nestlé. "In professional services, billing can be one of the more error-prone processes, with accuracy playing an important role in the client experience. SAP's Billing Assistant brings greater intelligence to this critical process, helping identify potential issues earlier so our people can deliver better client outcomes and build stronger relationships," said Jill Notz, Chief Accounting Officer, Controller, Business Services Leader, PwC. Building on the success of the Billing Assistant, PwC and SAP are extending their collaboration into new areas of joint AI innovation. SAP's Autonomous Enterprise Scales Up
Joule Work is beginning its customer rollout as a new AI user interface that lets employees interact with SAP solutions in their own language and complete work across SAP and third-party data. Grounded in business context from SAP Knowledge Graph, which maps more than 7 million data fields, Joule provides information users can rely on. At SAP, Joule Work is already live with 110,000 employees, with the company seeing 20% productivity gains across finance, HR and procurement. A select group of customers also is using Joule Work in their business environments.
"After 28 years as an SAP customer, partnering with SAP on our AI journey and the Joule Work Desktop early adopter program has delivered more momentum in just a few months than we saw in all the years before," said Peter Wied, Director of Complexity Management, Maschinenfabrik Reinhausen. "What once required up to an hour of manual effort across our S/4HANA environment is now accessible in seconds through natural language – fundamentally changing how our teams interact with business data." "The dedicated team has been phenomenal. Their proactive communication, focus on accelerating architecture activation, rapid remediation of defects, and overall support have enabled us to become Joule ready much sooner than would have been possible had we needed to navigate these challenges on our own," said Keith Smith, SAP Platform Architect, CONA Services. "The CONA team is excited about the progress made to date and looks forward to exploring and testing Joule's capabilities in greater depth over the coming months as we continue our adoption journey." When a query is not enough, Joule Assistants execute operational work directly within business workflows, using established data, authorizations and audit trails. Customers control the level of autonomy. SAP's approach is also open: through the Agent2Agent protocol, Joule can connect with third-party AI and agents, bringing governed business context into broader AI workflows.
At SAP Connect, SAP showcased how these capabilities generate outcomes across SAP Autonomous Suite:
In finance, controllers can automate revenue recognition, disclosures and trade compliance, with early deployments of the International Trade Assistant reducing trade classification effort by up to 50%. In supply chain, planners can turn multi-hour disruptions into one-click resolutions across planning, manufacturing and logistics. In HR, leaders can determine the best way to close workforce gaps, while employees can make smarter benefits choices tailored to their needs. In procurement, decision makers can identify savings opportunities against peer benchmarks and manage the full contingent workforce lifecycle. In customer experience, organizations can turn customer engagement into sales opportunities with AI-powered campaigns, quoting and customer workflows. Across industries, SAP is collaborating with customers to apply AI to specialized industry processes, helping organizations in manufacturing, retail, commodity trading and asset-intensive industries improve decision-making, automate routine actions and build more resilient operations. The Platform Powering Business AI You Can Trust
SAP Business AI Platform gives organizations one place to build, contextualize and govern AI across SAP and third-party environments. With Joule Studio, business users and developers can build and extend skills and agents from no-code to pro-code workflows, choosing from more than 70 AI models. SAP Business Data Cloud and SAP Knowledge Graph ground those agents in trusted business data and context, helping organizations select the right model for each use case and better manage AI value and consumption.
SAP-managed governance helps organizations scale AI with transparency, accountability and control. AI Agent Hub in SAP LeanIX solutions provides a central inventory of enterprise agents, while SAP's independently ISO/IEC 42001-certified governance architecture supports regulatory requirements, established authorizations and auditable AI operations.
To help organizations adopt AI at scale, SAP's Business Transformation Management portfolio, including SAP Signavio, SAP LeanIX and SAP WalkMe solutions, provides the toolchain to analyze processes, govern applications and agents, and drive adoption across the enterprise.
SAP Brings Embedded Payments to Cloud ERP
SAP also announced that it is entering the payments market with SAP Pay, powered by Tereina, an SAP company. Embedded directly in SAP Cloud ERP, SAP Pay executes and reconciles payments within the same workflow when an invoice is due, reducing manual file handling and external processing dependencies, while giving customers greater control.
Partners Expand the Reach of Autonomous Business
SAP is extending the Autonomous Enterprise beyond SAP's own application portfolio through new partnerships that bring specialized intelligence directly into SAP workflows.
A new partnership between SAP and Moody's Corporation is designed to embed Moody's supplier risk monitoring data into SAP Ariba Supplier Lifecycle and Performance. This gives procurement teams continuously updated insights into supplier financial health, operational risk and regulatory status at the point of decision. Organizations will be able to move from periodic risk reviews toward continuous monitoring, enabling Joule Agents to flag supplier risk signals and surface alternatives before disruption affects the business.
An expanded partnership with ORO Labs brings procurement orchestration to SAP customers as a solution extension. SAP Ariba Procurement Orchestration by ORO Labs is a purpose-built orchestration layer that connects procurement workflows end to end across heterogeneous enterprise environments, giving business users a seamless experience for intake, actions and visibility.
Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.
About SAP
As a global leader in enterprise applications and business AI, SAP (NYSE:SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com.
This press release was created with the assistance of artificial intelligence and has been reviewed by the editorial team.
This document contains forward-looking statements, which are predictions, projections, or other statements about future events. These statements are based on current expectations, forecasts, and assumptions that are subject to risks and uncertainties that could cause actual results and outcomes to materially differ. Additional information regarding these risks and uncertainties may be found in our filings with the Securities and Exchange Commission, including but not limited to the risk factors section of SAP's 2025 Annual Report on Form 20-F.
Note to editors:
To preview and download broadcast-standard stock footage and press photos digitally, please visit www.sap.com/photos. On this platform, you can find high resolution material for your media channels.
For customers interested in learning more about SAP products:
Global Customer Center: +49 180 534-34-24
United States Only: 1 (800) 872-1SAP (1-800-872-1727)
Please consider our privacy policy. If you received this press release in your e-mail and you wish to unsubscribe to our mailing list please contact [email protected] and write Unsubscribe in the subject line.
Tereina spustila službu SAP Pay, která zákazníkům SAP umožňuje platit dodavatelům, zaměstnancům a partnerům přímo z prostředí systému SAP, a to v běžných měnách i stablecoinech.
A logo on the SAP exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022.... Purchase Licensing Rights, opens new tab Read more
CompaniesOct 6 (Reuters) - Tereina, a payments company in which SAP (SAPG.DE), opens new tab owns a stake, on Tuesday launched technology that lets businesses pay suppliers, employees and affiliates directly from their SAP software in traditional currencies or stablecoins.
The launch introduces a payments layer inside business software that companies already use to track their money. Until now, SAP had stopped short of payments and let customers connect their own providers, Tereina CEO Cedric Bru said, while declining to disclose the size of SAP's stake in the company.
Sign up here.
SAP customers can subscribe to the new SAP Pay services under existing contracts
Bru compares the offering to Apple Pay as a payment service native to the system it runs in
Tereina was built with AI coding tools and the project ran for two and a half years, most of it in the past 18 months, with a staff of a few dozen in San Francisco
It partners with other payment providers rather than competing with them, claiming a 25% cut in payment costs
Reporting by Leo Marchandon in Gdansk, editing by Milla Nissi-Prussak
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Over the past 10 years, Costco (COST +0.31%) shares have climbed sixfold (as of Oct. 2). This has been an exceptional investment. That's true even though the retail stock trades 16% off its peak.
Is Costco a smart buy with $1,000 in October?
Image source: The Motley Fool.
There's no question that this is a high-quality business. Costco's warehouses see durable demand, as indicated by steady same-store sales growth. The company's massive size, with net sales totaling $297 billion in fiscal 2026 (ended Aug. 30), gives it a scale that supports a cost advantage, keeping prices low for shoppers.
Furthermore, the profitability streak is impressive. Costco consistently increases its earnings stream. Net income rose at a solid compound annual rate of 14.7% in the past decade.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
0.31
%) $
2.87
Current Price
$
923.52
The business continues to open new warehouses around the globe, which will drive future revenue and profit gains. At its current size, though, it's reasonable to assume that the growth will normalize. Plus, competition in the retail sector is always fierce.
Investors who haven't already should add Costco to their watch lists for now. It's not a screaming buy because the valuation is steep, with shares trading at a price-to-earnings ratio of 44.3. Market participants who favor quality over price, however, will have no issue adding the company to their portfolios.
But I believe that being patient is the best move right now.
Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Costco Wholesale. The Motley Fool has a disclosure policy.
Prior to the artificial intelligence (AI) revolution, Micron Technology (MU -1.02%) was doing its best to claw back from the usual down cycles of the memory market. Late last year the stock started to move higher, and the momentum carried over into 2026. So far this year, Micron stock has ripped 278%, launching the company into the trillion-dollar club.
What changed is simple: AI data centers started devouring high-bandwidth memory (HBM) and high-capacity DRAM faster than suppliers could produce. The question now is whether Micron's rally still has legs. There are 1.7 trillion reasons to think it does.
Image source: Micron Technology.
Micron is converting record sales into record profits Micron's financial performance in fiscal 2026 was absurd on every level. Full-year revenue hit $133 billion, up 256% from the prior year, while earnings per share (EPS) jumped nearly 900% to $74.
During the fourth quarter alone, the company delivered $54.2 billion in sales and $33 in EPS, with gross margin at 87%. Every segment of the business is going full throttle. The core data center unit generated $18 billion during the fourth quarter at a 90% gross margin. Cloud memory added another $16.3 billion at an 83% margin. Mobile and client, plus automotive and embedded, both cleared 84% margins or better.
The mix shift toward HBM and premium DRAM is the engine fueling Micron right now. Those products carry higher prices and better unit economics, so incremental revenue drops straight to the bottom line. Operating cash flow for the year reached nearly $90 billion and while adjusted free cash flow came in at $62 billion – nearly 20x higher than the year prior. With more than 75% of next year's shipments already under contract or allocation, Micron's cash machine does not look like it is about to stall.
MU Revenue (TTM) data by YCharts
Memory supply could be tight until 2028 Micron's CEO Sanjay Mehrotra suggested memory and storage will be tighter throughout fiscal 2027 and 2028 than they are today. The company's COO, Manish Bhatia, explained the structural brakes around memory, discussing how new technology transitions are delivering diminishing bit growth as HBM nodes take a rising share of industry wafers. Bhatia went on to say Micron simply does not have a clear line to "when supply and demand balances."
Wall Street seems to agree with Micron's management. Citi sees the memory shortfall widening through 2031 as DRAM growth accelerates 30% next year and another 35% in 2028. Meanwhile, JPMorgan's forecast values the memory market at $1.7 trillion by 2028, largely attributable to rising CPU demand alongside memory-intensive GPU systems.
Premium Feature
Moneyball Superscore
91/100
Today's Change
(
-1.02
%) $
-10.93
Current Price
$
1,063.96
How can Micron stock double? As of this writing (Oct. 2), Micron stock trades at roughly $1,080 per share. With a forward price-to-earnings (P/E) ratio near 6, this implies the market is modeling somewhere around $176 in earnings for the current fiscal year. Management's guidance for the first quarter points to about $38 in EPS on $61.5 billion of revenue. This implies the earnings run-rate is already there if profit margins hold.
MU PE Ratio (Forward) data by YCharts
Tight supply through 2028 gives Micron room to keep premium prices firm as its product mix continues shifting toward higher-value HBM4 and HBM4E. If earnings simply grow another 20 to 30% on top of the 2027 estimate, you are looking at about $220 in annual EPS by 2028. If I apply even a modest multiple expansion to 10 or 11 times earnings -- still well below historical peaks -- Micron stock could clear $2,000 without needing a massive rerating.
Given today's modest valuation profile multiple, the company's contracted backlog, and the multi-year supply gap, I think Micron stock could reasonably double before 2028 even happens. To me, this level of share price appreciation looks less like wishful thinking and more like a base case scenario so long as the memory shortage simply persists.
Micron žaluje YMTC kvůli údajnému přebírání inženýrů a zneužití důvěrného know-how při získání patentů použitých proti Micronu; žádá převod čtyř amerických patentů.
Micron is accusing a Chinese chip rival of a brazen scheme: poach its engineers, extract their confidential knowledge, then file patents on that knowledge to turn around and sue Micron with its own technology.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Micron Technology (NASDAQ:MU | MU Price Prediction) alleges that Chinese memory maker Yangtze Memory Technologies (YMTC) hired away its engineers, took confidential know-how, and patented versions of Micron’s technology to sue Micron. In a lawsuit filed in federal court in Idaho on September 15, 2026, Micron claims the patents being used against it were built on its own engineering.
Micron shares sit at $1,063.96, up 273.01% this year. The case concerns NAND flash (storage chips in phones and data centers), while most of Micron’s record $54.23 billion in quarterly revenue comes from DRAM, the working memory inside servers and computers.
What Micron Alleges in Idaho The complaint names eight former employees and claims some hid their new roles on professional networking profiles. News reports indicate at least 20 employees moved from Micron to YMTC.
Micron alleges YMTC used patents listing those former employees as inventors to sue Micron. It asks the court to transfer ownership of four US patents to Micron, plus injunctions and damages. No damages figure has been disclosed.
Memory is especially exposed to this kind of transfer because knowledge of manufacturing processes lives in engineers’ heads more than in documents. That is why engineers changing employers is common in memory trade-secret cases.
Three days after Micron filed in Idaho, a Munich court ruled for YMTC in two cases and ordered Micron to stop selling certain NAND products in Germany. Micron has appealed.
YMTC first sued Micron in California in November 2023 and has since filed in China, Texas, the United Kingdom, and Europe. Venue shopping explains Germany, where injunctions are relatively easy to obtain. A win there shows leverage more than it proves the underlying claims.
Last quarter Micron earned $39.8 billion from DRAM against $14.1 billion from NAND. The litigation impacts the smaller business.
A German sales ban on certain NAND products poses little threat to the investment case. That changes with an injunction in a larger market, an adverse ruling on patent ownership, or NAND growing into a larger share of revenue.
China Builds What It Cannot Buy US export controls have pushed Chinese producers to build memory capacity at home. That competition will grow regardless of this suit’s outcome, and over several years matters more to Micron than any single injunction.
Micron’s results also reflect an unusually strong pricing cycle. On September 30, 2026, management said: “we do not have line of sight to when supply and demand will return to balance.” Multi-year customer agreements now cover “over 35% of our revenue through 2030,” suggesting part of this boom is structural.
What Could Shift the Outlook for Micron The fundamentals look strong relative to the legal risk. Shares trade at 7 times forward earnings, and legal exposure is relatively small.
Guidance calls for fiscal first-quarter revenue of $61.5 billion ± $1.5 billion. The consensus analyst price target is $1,520.02.
That view would change with a loss on the German appeal, a YMTC injunction in the US or UK, or a court refusing to hand Micron the four patents. Watch YMTC’s response in Idaho and the DRAM-versus-NAND split in the next earnings report.
Contact [email protected] for any questions or corrections.
The rental market continues to show strength, with the biggest annual rent gain since April 2025
In September, existing home sales fell 2.5% from last year according to Zillow's nowcast. Newly pending sales, a forward-looking indicator of future closed sales, fell by 8.5% as mortgage rates reached their highest level since November 2023. A monthly mortgage payment on a typical home is 6.7% higher than a year ago, assuming a 20% down payment and excluding taxes and insurance. That's despite home values rising just 1% over the past year, according to the Zillow Home Value Index. The typical U.S. rent rose 2.7% from a year earlier to $1,932, the biggest annual gain since April 2025 according to the Zillow Observed Rent Index. , /PRNewswire/ -- Sky-high mortgage rates and the usual fall slowdown teamed up to chill housing activity, according to the Zillow® September Market Report. Closed sales of existing homes fell 2.5% from a year earlier, according to Zillow's preliminary nowcast. Newly pending sales, a leading indicator of future closings, fell 8.5% year over year.
Mortgage rates ended the month at 7.28%, the highest reading since November 2023 according to Freddie Mac. Home values remain little changed, up just 1% over the past year according to the Zillow Home Value Index. But higher rates have pushed the typical mortgage payment to be 6.7% higher than a year ago, assuming a 20% down payment and excluding taxes and insurance.
Despite more inventory, sales remain muted as buyers grapple with rising costs. There were 0.4% more new listings than last September, though that is 11.9% below the pre-pandemic baseline. Total for-sale inventory was 2.5% higher than a year ago, marking the 34th consecutive month of annual gains.
The for-sale market's retreat may be translating to rising costs in the rental market. The typical U.S. rent rose 2.7% year over year in September, the biggest annual gain since April 2025 according to the Zillow Observed Rent Index. Annual rent growth has accelerated every month since April and is widespread, rising for both multifamily and single-family homes.
"The for-sale market's slowdown was predictable given where mortgage rates currently stand, but the continued strength in the rental market is more surprising. Buyers on the margins are finding the monthly savings for renting too good to pass up, even if their long-run goal is still to purchase a home," said Mischa Fisher, chief economist at Zillow. "We expect sales to remain lower than last year through the fourth quarter. However, it's not out of the question that rates will decline as rapidly as they rose, which would bring both buyers and sellers back to the market. At this point in the calendar, the question is whether they would sit out until next spring."
More data, including dashboards with local market data, can be found on the refreshed Zillow Research website. The Zillow October Market Report is expected to be released November 5.
Home Values & Mortgage Payments
The typical U.S. home value is $366,913. The Zillow Home Value Index (ZHVI) fell 0.5% month over month in September. Home values are 1% higher than a year earlier. The monthly mortgage payment on a typical U.S. home is $1,922, assuming a 20% down payment and excluding taxes and insurance. That is 6.7% higher than last year. Inventory
There were 1.39 million homes for sale nationwide in September. Active inventory was 2.5% higher than a year earlier. Inventory fell 1.5% from August. New for-sale listings totaled 343,311 in September, up 0.4% from a year earlier and down 3.9% from August. Sales
319,346 homes were sold in September, according to the preliminary Zillow sales count nowcast. That is 2.5% lower than a year earlier and down 5.6% from August. These figures will be revised mid-month. Newly pending sales, which measures listings that changed from for-sale to pending status rather than closed sales, shows an 8.5% decrease from a year earlier and a 11.2% decrease over August. Affordability
A household earning the median income would need to spend 34.3% of its income on the typical monthly mortgage payment (assuming a typically valued home and a 20% down payment, and including estimates for taxes, maintenance and insurance). That is up from 33.7% a year earlier and 33.9% in August. A household earning the median income would need to spend 26.3% of its income on the typical rent in September. That is down from 26.4% a year earlier and flat from August. Competition
Homes took a median of 29 days to go pending in September. That was two days longer than a year earlier and two days longer than August. The share of listings with a price cut in September was 27.4%. That was up from 26.2% a year earlier and up from 26.3% in August. 27.6% of homes sold above list price in August, the most recent data available. That's compared to 26.9% a year earlier and 29.6% in July. Rents
The typical rent nationwide is $1,932, according to the Zillow Observed Rent Index. That's 2.7% higher than a year earlier and up 0.1% from August. 39.6% of rental listings on Zillow offered a concession in September. That's up from 37.4% a year earlier and up from 39.3% in August. Zillow September Market Report
Metro Area*
Typical
Home
Value
(ZHVI)
Home
Value
Change:
MoM
Home
Value
Change:
YoY
Inventory
Change:
YoY
Sales
Count
Nowcast
Change:
YoY
Typical
Rent
(ZORI)
Rent
Change:
MoM
Rent
Change:
YoY
United States
$366,913
-0.5 %
1 %
2.5 %
-2.5 %
$1,932
0.1 %
2.7 %
New York, NY
$733,217
-0.2 %
4.8 %
3 %
-2.2 %
$3,546
-0.1 %
4.2 %
Los Angeles, CA
$952,830
-0.5 %
1.3 %
0.5 %
-5.2 %
$2,929
0.2 %
1.8 %
Chicago, IL
$358,074
-0.2 %
5.1 %
0.1 %
1 %
$2,163
-0.2 %
4.7 %
Dallas, TX
$359,178
-0.5 %
-1.9 %
-3.9 %
-2.4 %
$1,659
0 %
0.7 %
Houston, TX
$303,039
-0.5 %
-1.8 %
2.4 %
-7.2 %
$1,638
0 %
0.1 %
Washington, DC
$570,871
-0.7 %
0.1 %
13.2 %
-8.8 %
$2,407
0.2 %
1.4 %
Philadelphia, PA
$387,304
-0.5 %
2.4 %
7.3 %
-7 %
$1,903
0 %
3.3 %
Miami, FL
$478,411
0 %
0.9 %
-13.9 %
-3 %
$2,654
0.2 %
1.8 %
Atlanta, GA
$376,082
-0.5 %
-1.6 %
1.3 %
-11.2 %
$1,843
0.2 %
2.1 %
Boston, MA
$728,324
-0.7 %
1.9 %
15 %
-0.4 %
$2,987
-0.6 %
2.3 %
Phoenix, AZ
$440,821
-0.4 %
-1.1 %
4.4 %
-5.1 %
$1,720
0.1 %
1 %
San Francisco, CA
$1,131,146
-0.3 %
3.7 %
-12.3 %
-2.6 %
$3,445
1.2 %
11.8 %
Riverside, CA
$581,604
-0.3 %
0.5 %
-3.8 %
-2.6 %
$2,533
0.2 %
2.9 %
Detroit, MI
$264,838
-0.7 %
1.5 %
6.6 %
-7.7 %
$1,514
0.4 %
4.2 %
Seattle, WA
$721,838
-1.1 %
-2.2 %
20.3 %
-8.7 %
$2,250
-0.2 %
1.8 %
Minneapolis, MN
$389,947
-0.3 %
1.7 %
16.8 %
0.4 %
$1,736
-0.1 %
3.5 %
San Diego, CA
$929,618
-0.6 %
0.9 %
-4.9 %
-9.3 %
$2,967
0 %
2.2 %
Tampa, FL
$357,180
-0.4 %
-0.5 %
-6.2 %
0.5 %
$1,991
0.2 %
0.4 %
Denver, CO
$557,532
-0.8 %
-1.7 %
0.4 %
-8.1 %
$1,900
-0.2 %
0 %
Baltimore, MD
$397,069
-0.7 %
0.2 %
9.1 %
-2.9 %
$1,937
0.3 %
2.7 %
St. Louis, MO
$274,292
-0.5 %
3.1 %
6.8 %
-4.2 %
$1,427
0.3 %
4.1 %
Orlando, FL
$383,561
-0.2 %
-1.2 %
-1.8 %
5.9 %
$1,929
-0.3 %
0.8 %
Charlotte, NC
$381,219
-0.7 %
-1.2 %
5.7 %
-0.2 %
$1,735
0.1 %
1.4 %
San Antonio, TX
$273,869
-0.7 %
-1.9 %
3.3 %
3.3 %
$1,415
0 %
-0.7 %
Portland, OR
$541,200
-0.6 %
-0.1 %
4.5 %
-2.8 %
$1,803
0.3 %
1.1 %
Sacramento, CA
$574,555
-0.5 %
0.2 %
-1.6 %
-0.3 %
$2,269
0.1 %
1.8 %
Pittsburgh, PA
$229,242
-0.6 %
0.4 %
11.7 %
-3.1 %
$1,467
0.1 %
3.5 %
Cincinnati, OH
$306,903
-0.5 %
1.9 %
6.3 %
3.2 %
$1,522
0.2 %
2.8 %
Austin, TX
$416,134
-0.7 %
-3.9 %
-2.5 %
-0.5 %
$1,603
0 %
0.7 %
Las Vegas, NV
$422,534
-0.5 %
-2.7 %
3.7 %
-2.5 %
$1,732
-0.1 %
0.5 %
Kansas City, MO
$327,069
-0.4 %
3.5 %
0.7 %
0.2 %
$1,534
0.1 %
3.8 %
Columbus, OH
$328,082
-0.6 %
1.1 %
5.5 %
0.1 %
$1,525
0.2 %
2.9 %
Indianapolis, IN
$292,332
-0.4 %
0.9 %
10.8 %
0.2 %
$1,528
0.2 %
3.5 %
Cleveland, OH
$251,602
-0.4 %
3.8 %
16.6 %
-1.2 %
$1,440
0.4 %
4.5 %
San Jose, CA
$1,535,288
-1 %
-0.2 %
10.5 %
2 %
$3,812
0.7 %
8.3 %
Nashville, TN
$449,730
-0.5 %
-0.6 %
9.6 %
2.7 %
$1,803
0.1 %
1.2 %
Virginia Beach, VA
$372,867
-0.3 %
2.8 %
4.8 %
-1.8 %
$1,886
0.6 %
7.1 %
Providence, RI
$524,593
-0.3 %
3.5 %
10.7 %
-9.3 %
$2,166
-0.2 %
4.2 %
Jacksonville, FL
$351,310
-0.1 %
0.2 %
-12.4 %
3.5 %
$1,680
0.3 %
2.2 %
Milwaukee, WI
$386,695
-0.6 %
4.9 %
4.4 %
2.2 %
$1,549
0.2 %
5.1 %
Oklahoma City, OK
$243,587
-0.5 %
0.7 %
5.4 %
7.5 %
$1,384
0.3 %
2.4 %
Raleigh, NC
$427,969
-0.7 %
-1.8 %
11.1 %
3.9 %
$1,669
0.2 %
1.4 %
Memphis, TN
$241,929
-0.7 %
-0.2 %
8 %
-1.4 %
$1,393
-0.1 %
1.1 %
Richmond, VA
$394,095
-0.4 %
2.5 %
8.3 %
2.1 %
$1,706
-0.3 %
2.5 %
Louisville, KY
$279,064
-0.5 %
1.3 %
16 %
7.2 %
$1,339
0.3 %
2 %
New Orleans, LA
$256,676
-0.9 %
0.8 %
-0.3 %
-2.5 %
$1,577
-0.1 %
1.7 %
Salt Lake City, UT
$560,853
-0.4 %
0.5 %
8.9 %
-3.3 %
$1,644
-0.1 %
0.7 %
Hartford, CT
$401,131
-0.3 %
5 %
5.6 %
2.9 %
$1,998
0.1 %
3.5 %
Buffalo, NY
$287,962
-0.6 %
3.1 %
15.2 %
6.3 %
$1,451
0.4 %
3.8 %
Birmingham, AL
$261,464
-0.4 %
2.3 %
1.6 %
4.8 %
$1,404
0.5 %
2.9 %
*Table ordered by market size
Forward-looking statements
This press release includes forward-looking statements about future housing market conditions, mortgage rates, rental trends and other economic factors. These statements are based on current expectations and assumptions, which are subject to change. Actual outcomes may differ materially due to changes in economic and market conditions. Forward-looking statements speak only as of the date of this release, and Zillow Group undertakes no obligation to update them.
About Zillow Group
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.
As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.
Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.
Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.
MercadoLibre's revenue is growing at its fastest pace in four years, yet the stock keeps sliding while profits shrink and earnings estimates drift lower. One Wall Street analyst sees a massive rebound ahead, but his case depends on a single…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
MercadoLibre (NASDAQ:MELI | MELI Price Prediction) currently trades at $1,860.61, while Wall Street’s average price target stands at $2,269.94. That leaves a gap of roughly 22% separating the stock from where analysts think it belongs.
MercadoLibre runs Latin America’s dominant e-commerce marketplace alongside Mercado Pago, a fintech arm spanning payments, credit cards and lending. Quarterly revenue just reached $10.17B, up 49.8%, its fastest growth in four years.
The most bullish analysts goes further. Scotiabank’s Hector Maya holds a Street-high $2,800 target with a Sector Outperform rating. That implies about 50.5% upside, a gap large enough to demand scrutiny.
Record Sales, Shrinking Profits Sent MercadoLibre Lower Margins drove the decline. Operating margin contracted 550bps to 6.7% in Q2, and operating income fell 17.2% to $683M even as sales surged. Management calls it deliberate: lower free shipping thresholds in Brazil, heavy credit card issuance, first-party inventory, cross-border trade from China, PIX discounts, and AI spending roughly $80 million higher than a year ago.
Back-to-back misses had already worried investors. Q3 2025 EPS of $8.32 missed by 10.51%, and Q4 2025 EPS of $11.03 missed by 6.92%. Argentine peso weakness, Mexico tax reform and net debt rising to $6.4B from $4.7B added pressure. Even the Q2 beat failed to help, with shares slipping from $1,893.20 to $1,820.69 a day later.
22 of 26 Analysts Still Call MercadoLibre a Buy Of 26 analysts, 5 give it a Strong Buy, 17 a Buy and 4 a Hold, with zero Sells. Their evidence: ecosystemic users grew 37%, assets under management rose 68% to $23B, and advertising grew 62% FX-neutral. In Brazil, conversion improved 1.1 percentage points after the free shipping change.
Maya cut his target from $3,500 after the margin reset but kept his Outperform call, viewing the dip as an entry point. His thesis rests on the Mercado Envios logistics moat, Mercado Pago converting unbanked users into credit customers, high-margin ads offsetting fulfillment costs, and barriers that keep Shopee and Amazon (NASDAQ:AMZN) at bay.
Credit cards set the timeline. Management says each cohort breaks even after 12 to 18 months, and Brazil issuance jumped to 2.6 million cards from 1.6 million a year earlier. Card NIMAL stands at -2.5%, so maturing cohorts are the swing factor for 2027 earnings.
Estimates are drifting lower, though. The 2026 EPS consensus of $38.167 drew 12 downward revisions against 2 upward over 30 days. Targets are opinions, and the inputs behind them are moderating.
Sea Limited Fell Harder While Amazon Climbed MercadoLibre has company in its decline, but the peer group split sharply.
Sea Limited (NYSE:SE), whose Shopee competes directly in Brazil, dropped 48.89% over 12 months to $96.85. Its average target of $155.11 implies roughly 60.2% upside, with 27 of 29 analysts at Buy or Strong Buy. The story rhymes: revenue grew 48.1% while credit loss provisions jumped 71.5%.
Amazon rose 13.81% over the year to $251.40. Its average target of $330.59 implies about 31.5% upside, and 58 of 60 analysts rate it Buy or better.
Sea holds the group’s largest consensus-implied upside. MercadoLibre’s consensus gap trails both peers, and only Scotiabank’s target pushes it near Sea’s territory.
A 14% Slide Against a Rising S&P 500 At $1,860.61, MercadoLibre sits roughly 22% below its $2,269.94 consensus target from 26 analysts. Shares are down 14.37% over one year and 7.63% year to date. The S&P 500 gained 15.78% over one year and 13.62% year to date.
Momentum just turned. The stock rose 8.65% in the past week, including a 9.67% jump in the latest session. The forward P/E of 33 compares with a trailing 46, inside a 52-week range of $1,495 to $2,428.
MercadoLibre Rewards Patience, but the $2,800 Target Is a Stretch The outlook improves if credit card cohorts mature on schedule and margins steady near current levels while revenue keeps growing above 40%. That path, plus ads and AI efficiencies (customer-service reps fell from 10,000 to 7,000), could revive earnings growth in 2027. The thesis weakens if EPS revisions keep falling, Argentina’s currency weakens again, or rising debt funds a loan book that sours in a Brazilian slowdown.
My take is bullish. The consensus target looks reachable as cohorts mature, while the $2,800 call needs everything to go right. Investors should keep an eye on margins and credit quality in the next earnings report.
Contact [email protected] for any questions or corrections.
Philip Morris ve 2. čtvrtletí zaznamenal organický růst tržeb o 7,6 % a růst upraveného zisku na akcii o 15 %, podpořený cenotvorbou a bezkouřovými produkty.
SummaryPhilip Morris is a growth and income play, leveraging its transition to smoke-free products for robust total returns.PM delivered Q2 organic revenue growth of 7.6% and adjusted EPS up 15%, driven by strong pricing, resilient combustibles, and an expanding NGP portfolio.The stock yields 3.4%, recently raised its dividend by 8.8%, and maintains an A- rated balance sheet.I rate PM a 'Buy,' expecting mid-teens annual total returns as smoke-free products drive future growth.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » Irina Esau/iStock via Getty Images
“Diamond Hands” is a term that refers to holding high-conviction stocks without the need to sell. Like many expressions, that’s easier said than done. What makes it easier to accomplish is if the underlying holding pays you a
23.62K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of PM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Regeneron na ESMO 2026 představí 10 abstraktů včetně údajů o celkovém přežití při přibližně tři a půlletém mediánu sledování ze studie fáze 3 C-POST s přípravkem Libtayo u pacientů s vysoce rizikovým CSCC.
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC
New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants
TARRYTOWN, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new clinical research at the European Society for Medical Oncology (ESMO) Congress 2026, taking place from October 23-27 in Madrid, Spain. Highlights from the company’s 10 abstracts will cover new data and analyses from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma and cancer-associated thrombosis.
“At ESMO, we look forward to sharing data across a range of conditions reflecting the breadth of our research,” said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. “For the first time, we’re showcasing how our work extends beyond the treatment of cancer itself, and addresses some of the complex challenges patients face as a result of their disease. Together, these data reflect our broader commitment to advancing comprehensive cancer care for patients.”
Highlights include:
Adjuvant treatment with Libtayo in adults with CSCC with high risk of recurrence after surgery and radiation: Late-breaking overall survival (OS) data at approximately 3.5 years follow-up from the C-POST Phase 3 trial will provide further evidence supporting Libtayo as the standard of care in this indication. Neoadjuvant treatment with Libtayo in stage II-IV CSCC: Data include the final analysis of Phase 2 results, which represent the most mature data set in patients treated with Libtayo prior to surgery.Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer: Data include a Phase 2 sub-analysis and modeling in catheter-related VTE, plus an update on the Phase 3 ROXI-CAT-II trial. The full list of Regeneron presentations at ESMO are as follows:
Abstract TitleAbstractPresenterSession Date/Time (CET)Skin CancerC-POST Phase 3 trial of adjuvant cemiplimab vs. placebo for high-risk CSCC: OS update at approximately 3.5 years' median follow-upLBA: 59
Danny RischinSunday
October 25,
10:15-11:45A Phase 2 study of neoadjuvant cemiplimab for Stage II--IV CSCC: final analysisPoster presentation: 2490PNeil D. GrossSaturday
October 24,
12:00-12:45Long-term Overall Survival (OS) with Fianlimab (FIAN) plus Cemiplimab (Cemi) in Advanced Melanoma (aMel): Survival Follow-up of a Phase 1 StudyPoster presentation: 2091POmid HamidSaturday
October 24,
12:00-12:45Lung CancerImpact of objective response on PROs in patients receiving cemiplimab + chemotherapy vs. placebo + chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2Poster presentation: 2714PKonstantin PenkovMonday
October 26,
12:00-12:45CEMI-LUNG, a European-based observational study to assess cemiplimab real world effectiveness and safety in patients with advanced non-small cell lung cancerPoster presentation: 2580PJesus Corral JaimeMonday
October 26,
12:00-12:45Ovarian CancerCirculating tumor DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum-resistant ovarian cancer treated with ubamatamabPoster presentation: 1957PJung-Yun LeeSaturday
October 24,
12:00-12:45A Phase 1/2 study of REGN5668 (ubamatamab) (mucin 16 [MUC16] × cluster of differentiation [CD]28 costimulatory bispecific antibody), in combination with other targeted therapies, in patients with recurrent ovarian cancer or endometrial cancer: Trial in progress updateePoster presentation: 1445eTiPRoisin E. O'CearbhaillN/AThrombosis (cenvacibart [REGN7508] and amrecibart [REGN9933])Phase 3 trial-in-progress evaluating cenvacibart for the treatment and secondary prevention of venous thromboembolism (VTE) in participants with solid and hematologic cancers (ROXI-CAT-II)ePoster presentation: 1534eTiPAndrés J. MuñozN/ASub-analysis of a Phase 2 study investigating amrecibart and cenvacibart for the prevention of contact-mediated VTE in participants with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH)Poster presentation: 1468PJeffrey I. ZwickerMonday
October 26,
12:00-12:45Population pharmacokinetic/pharmacodynamic modeling of REGN7508Cat in patients with a PICC from ROXI-CATH who have active cancer supports maximal Factor XI pathway inhibitionPoster presentation: 3968PJeffrey I. ZwickerSaturday
October 24,
12:00-12:45
The potential uses of neoadjuvant Libtayo in CSCC, ubamatamab, cenvacibart and amrecibart described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.
About Regeneron in Cancer
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.
Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations.
To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care.
About Libtayo
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced NSCLC and advanced cervical cancer.
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab.
The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.
U.S. FDA-approved Indications
Libtayo is a prescription medicine used to treat:
Adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC): that has spread or cannot be cured by surgery or radiation, orto help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation. Adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene. It is not known if Libtayo is safe and effective in children.
IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
What is the most important information I should know about LIBTAYO?
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
Lung problems: cough, shortness of breath, or chest painIntestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tendernessLiver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normalHormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulnessKidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetiteSkin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodesProblems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruisingInfusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swellingRejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have hadComplications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.
Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:
have immune system problems such as Crohn’s disease, ulcerative colitis, or lupushave received an organ or tissue transplant, including corneal transplanthave received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)have received radiation treatment to your chest areahave a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndromeare pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby
Females who are able to become pregnant: Your healthcare provider will give you a pregnancy test before you start treatmentYou should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this timeTell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC, or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia).
The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching.
The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite.
These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296.
Please see full Prescribing Information, including Medication Guide.
About Regeneron's VelocImmune® Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara®, Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn), Veopoz® (pozelimab-bbfg) and Pasatru™ (garetosmab-grts). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. A total of 11 antibody and bispecific products have been approved or authorized worldwide that were invented or derived using VelocImmune technologies.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Libtayo® (cemiplimab) as an adjuvant or neoadjuvant treatment for high-risk cutaneous squamous cell carcinoma, Regeneron’s Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer, and the other clinical programs discussed or referenced in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as those referenced above; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
Spencer Stiles se od 1. ledna 2027 stane generálním ředitelem společnosti Stryker a nahradí Kevina Loba, který přejde do funkce výkonného předsedy představenstva.
Kevin Lobo to transition to Executive Chair of the Board of DirectorsCurrent President and COO Spencer Stiles appointed Chief Executive OfficerLeadership transition effective January 1, 2027
Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company’s Board at that time.
Lobo has led a distinguished career at Stryker spanning more than 15 years. He joined the company in 2011 as Group President, became Chief Executive Officer in October 2012 and was appointed Chair of the Board in July 2014. During his transformative 14-year tenure as CEO, Lobo significantly expanded Stryker’s portfolio and global presence and tripled annual net sales from $8.7 billion in 2012 to more than $26 billion in 2026. Under his leadership, Stryker has completed more than 60 acquisitions, including Mako, which combined pioneering robotic-arm-assisted technology with Stryker’s joint-reconstruction expertise to transform the orthopaedic industry, strengthening Stryker’s position as a diversified global leader in medical technologies. Lobo also helped shape the culture that defines Stryker today, establishing its mission to make healthcare better together with its customers, while advancing a specialized business operating model that has supported the company’s distinctive performance and growth.
“Serving as CEO of Stryker has been an incredible honor, and I am proud of all that our teams have accomplished together on behalf of our customers and the patients they serve,” said Lobo. “The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition. Having worked alongside Spencer for many years, I have seen firsthand the qualities that define his leadership: his ability to set a clear direction, inspire people and translate strategy into strong execution. He understands what makes Stryker unique and has the judgment, experience and commitment to our mission and values to build on our momentum and lead the company forward. I look forward to working with Spencer to ensure a smooth transition and to continuing to support Stryker as Executive Chair of the Board.”
“I am honored to be named Stryker’s next CEO and grateful to the Board and Kevin for their trust in me,” said Stiles. “I have a deep appreciation for our people, our culture and the customer relationships that drive our innovation and growth. Kevin has built an extraordinary legacy and a strong foundation for the future, which I am excited to build upon as we continue executing our strategy, driving growth and advancing our mission to make healthcare better.”
Stiles is a strategic, growth-oriented and people-focused leader with a proven record of execution throughout his distinguished career at Stryker spanning nearly three decades. Since joining the company’s Endoscopy business in 1999, he has held leadership roles across nearly every Stryker business, spanning Orthopaedics, MedSurg and Neurotechnology. Before becoming President and Chief Operating Officer in January 2026, Stiles served as Group President, Orthopaedics, leading the company’s Joint Replacement and Trauma & Extremities businesses and its Digital, Robotics and Enabling Technologies organization, with additional responsibility for international regions and Stryker’s enterprise mergers and acquisitions strategy. He has also led significant portfolio initiatives, including the acquisition of Wright Medical, which enhanced Stryker’s global market position in trauma and extremities, and the separation of the company’s spinal implants business.
“This announcement is the culmination of a comprehensive, long-term succession planning process,” said Sheri McCoy, Lead Independent Director of Stryker’s Board of Directors. “Spencer is a proven leader with strategic perspective and the ability to unite teams around shared priorities. The Board is confident that he is the right leader to build upon Stryker’s momentum and guide the company’s next chapter. On behalf of the Board, I also want to recognize Kevin for his exceptional leadership and service over his tenure as CEO. Kevin has positioned Stryker to enter this transition from a place of strength. With a mission-driven culture, clear strategic direction and a strong leadership team, Stryker is poised to capture the significant opportunities ahead. We are fortunate that we will continue to benefit from his experience and perspectives as Executive Chair.”
Forward-Looking Statements
This press release contains forward-looking statements subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy, growth prospects and opportunities, and the Company’s ability to execute on its priorities during and following the transition. These forward-looking statements involve various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: risks associated with the transition of executive leadership and the ability of Mr. Stiles and the Company’s executive team to execute on the Company’s strategy and business plans; the Company’s ability to retain key personnel during and after the transition; and other risks listed or described from time to time in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]
Aetna od 1. září u způsobilých příjemců Medicaid v osmi státech sloučila schvalování onkologické léčby, ozařování a vyšetření CT či MRI z průměrně čtyř samostatných žádostí do jedné.
A lymphoma patient on Medicaid can face four separate insurance permission slips before her first treatment begins, and every one of those gates is a chance for her care to stall. Aetna is rethinking that process in eight states, but…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A grandmother on an Aetna Medicaid plan diagnosed with lymphoma faces a treatment plan that builds fast: chemotherapy or immunotherapy, radiation, and CT or MRI scans. Her oncology office could expect to file four separate prior authorizations to get that plan approved, which is Aetna’s own average for a member needing cancer treatment.
Aetna is cutting that stack down to one. CVS Health (NYSE:CVS | CVS Price Prediction) says its Aetna unit now bundles those approvals into a single request for eligible Medicaid members in Oklahoma, Illinois, Maryland, New Jersey, Virginia, Florida, Kentucky and West Virginia. The expansion covers all cancer types and took effect September 1.
How Aetna’s Oncology Bundle Turns 4 Requests Into 1 Prior authorization is the insurer’s permission slip. Before the plan pays for an expensive drug, scan or procedure, the doctor’s office sends clinical records and waits for approval. Cancer care generates enough of these slips to cover a waiting room because treatment rarely involves just one service.
Aetna’s bundle combines medical oncology, including chemotherapy and immunotherapy where appropriate, and/or radiation oncology services with associated high-tech imaging needs, such as MRI or CT scans, into one request submitted through a single portal. That portal is Eviti. The eight-state eligibility applies to providers that utilize the Eviti portal to submit prior authorizations.
Aetna tested the idea on a narrower rollout first. In that phase, almost 25% of eligible members received a bundled authorization, according to the company’s September 17, 2026 announcement.
“By approving a broader set of treatments and related services upfront, we’re removing barriers that can delay care,” said Katerina Guerraz, Aetna’s chief operating officer and president of Medicaid, in the announcement. “Oncologists have the flexibility to make care decisions as treatment plans evolve.”
Fewer Approval Cycles Mean Fewer Chances for Treatment to Stall Every separate authorization creates a gate. The office files, waits, answers follow-up questions and sometimes appeals. A patient who just finished a chemo cycle can face another wait while the radiation request moves through approval.
Bundling those services can reduce paperwork and the chances that treatment stalls while the office goes back for another authorization. Fewer cycles mean fewer fax-machine standoffs between clinic and plan reviewer.
Doctors feel the drag, too. In Aetna’s latest provider survey, 74% of providers called administrative burden the top challenge facing clinical staff, and 31% named prior authorization management as the single largest cause. 80% expect to save more than 30 minutes a day through tools like bundles.
Medicaid is the joint federal-state program serving eligible people with limited income, including millions enrolled through state Medicaid plans. For now, the expanded bundle applies to eligible Aetna Medicaid members in the eight participating states whose providers submit through Eviti. Aetna expects to extend eligibility to Medicare and commercial members in the first half of 2027.
Geography matters as well. Each state runs its own Medicaid program, so covered drug lists, imaging rules and provider networks shift from state to state. Aetna Medicaid members outside the eight listed states, or whose oncologist doesn’t file through Eviti, fall outside the current rollout.
Coverage, Network and Medical-Necessity Rules Still Apply The bundle speeds up the paperwork and leaves the rulebook intact. It does not override covered-benefit rules, network requirements or medical-necessity standards.
In practice, a drug the state’s Medicaid plan bars stays bars. An out-of-network radiation center stays out of network. A reviewer still checks that the proposed treatment fits the clinical evidence before the approval comes through.
Families who ask a few direct questions early tend to avoid surprises later. The first set goes to the plan and the oncology practice:
Does this practice submit through Eviti and use the bundled process for Medicaid members? Does this patient’s plan qualify for the bundle in her state? The second set covers each piece of the treatment plan:
Is every drug on the plan’s covered list? Are the imaging center and the radiation facility in network, along with the oncologist? If the treatment plan changes midway, does the existing bundle cover the new service, or does the office need a fresh request? Adult children helping a parent through treatment can handle these calls. Reaching out to the plan’s member services line before the first infusion beats discovering a coverage problem three weeks in.
One authorization removes the repeat gates that slow cancer care, while coverage, network and medical-necessity rules still mark the boundaries. Families who confirm those details at the first appointment should receive the full benefit of the faster process.
Contact [email protected] for any questions or corrections.
Prologis má ve třetím čtvrtletí vykázat zisk na akcii ve výši 0,78 USD a tržby 2,22 miliardy USD, oproti loňským 0,80 USD na akcii a 2,05 miliardy USD.
Prologis, Inc. (NYSE:PLD) will release its third quarter earnings report before the opening bell on Thursday, Oct. 15.
Analysts expect the Maryland-based company to report quarterly earnings of 78 cents per share, down from 80 cents per share in the year-ago period. The consensus estimate for PLD’s quarterly revenue is $2.22 billion. It reported $2.05 billion last year, according to Benzinga Pro.
On Aug. 4, Prologis announced an approximately $2.1 billion public offering of 15 million shares.
Shares of Prologis fell 0.6% to close at $128.08 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Wells Fargo analyst Blaine Heck maintained an Overweight rating and cut the price target from $167 to $166 on Sept. 1, 2026. This analyst has an accuracy rate of 52%. RBC Capital analyst Michael Carroll upgraded the stock from Sector Perform to Outperform and boosted the price target from $148 to $160 on Aug. 5, 2026. This analyst has an accuracy rate of 64%. Scotiabank analyst Nicholas Yulico maintained a Sector Perform rating and increased the price target from $146 to $150 on July 23, 2026. This analyst has an accuracy rate of 58%. Truist Securities analyst Michael Lewis maintained a Buy rating and raised the price target from $154 to $162 on July 21, 2026. This analyst has an accuracy rate of 61%. Mizuho analyst Vikram Malhotra maintained an Outperform rating and raised the price target from $150 to $159 on July 17, 2026. This analyst has an accuracy rate of 54%. Considering buying PLD stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Akcie McCormick v září klesly o 16 % kvůli rostoucím nákladům na potraviny a opatrnějším spotřebitelům, přestože výsledky za třetí čtvrtletí překonaly očekávání.
Rising food prices in the U.S. weren't doing our comestibles industry any favors in September. They made finished food products more expensive to produce, and compelled consumers to be more cautious about their grocery shopping.
None of this was particularly good for spices, condiments, and flavorings specialist McCormick (MKC +1.95%), as evidenced by the stock's 16% decline over the course of that month. Did the company deserve the drubbing it took, however? I have my doubts.
Image source: Getty Images.
Losing its flavorOn the last day of August, a team of analysts from Bank of America (BAC +0.47%) published an update on consumer staples stocks. In their view, those rising costs will continue to put the squeeze on such companies for the rest of the year. Compounding that, these businesses have limited scope for raising prices further, given the already notable inflation in foodstuffs.
The bank's prognosticators flagged two key factors in this. The first is the steep rise in fuel costs, particularly diesel, which powers many of the trucks that ship food products around this country. The second is the Russia-Ukraine war, which is driving up prices of food industry inputs.
The analysts identified eight companies that they feel will continue to come under pressure from these factors. The ray of sunshine, in their view, is that as a specialized business, McCormick will not be as badly affected as a broader food company like Conagra (CAG -1.27%) or Pilgrim's Pride (PPC +1.78%).
Still, some professionals tracking the company were losing their optimism. On Sept. 14, TD Cowen's Robert Moskow went as far as to downgrade his recommendation on McCormick. For him, the stock is now a hold with a price target of $55 per share; previously, he had pegged it as a buy at a fair value assessment of $60. Several days later, his peer at JPMorgan Chase (JPM +0.00%) unit J.P. Morgan, Thomas Palmer, shaved $1 off his price target to $62 per share. However, he maintained his overweight (i.e., buy) recommendation on the shares.
Premium Feature
Moneyball Superscore
62/100
Today's Change
(
1.95
%) $
0.87
Current Price
$
45.54
October surprise?McCormick had a September to forget, but the stock didn't stay in the dumps for long. On the back of a better-than-expected third quarter, the results of which were published Oct. 1, it's staged something of a recovery. The fact that it's still down from its level at the start of September, though, shows that investors remain wary of its future.
I don't think they need to be so cautious. Long ago, McCormick established a solid foothold in its flavorings/condiments niche. As an ace operator in this limited field, it knows how to keep margins relatively high for the food industry, and throw off enough cash to pay a high-yield dividend that's been raised for 40 years in a row. Its fundamental growth hasn't been hot, admittedly, and that probably won't change, but at 4.2%, that yield sure is spicy. Also, due to the specialized nature of its business, McCormick typically trades at a forward P/E over 20; it's now at a beaten-down level of 14, which I believe is unsustainable long-term.
Yes, it will feel the squeeze from food prices, especially if they continue to rise past New Year's, but I'd be optimistic that this trend will cool in the coming months.
Knight Therapeutics získala v Brazílii urychlené regulační schválení v režimu pro vzácná onemocnění přípravku NIKTIMVO pro pacienty ve věku od 6 let s hmotností nejméně 40 kg s chronickou reakcí štěpu proti hostiteli po selhání nejméně dvou systémových terapií.
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1
“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class mechanism that targets the underlying drivers of this debilitating condition, and we are proud to bring it to patients in Brazil. This approval reflects the strength of our partnership with Incyte and our shared commitment to ensuring that patients in Brazil have access to innovative therapies that can make a meaningful difference in their lives,” said Samira Sakhia, President and CEO of Knight Therapeutics.
In September 2021, Knight and Incyte (NASDAQ: INCY) had entered into an exclusive supply and distribution agreement for MINJUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) in Latin America. In August 2025, Knight expanded its existing relationship with Incyte, to add exclusive rights to distribute ZYNYZ® (retifanlimab) and NIKTIMVO® (axatilimab) in Latin America. Under the terms of the amended agreement, Incyte is responsible for the development, manufacture and supply of such products to Knight, and Knight is responsible for seeking the necessary regulatory approvals and commercializing such products in Latin America.
About NIKTIMVO®
NIKTIMVO® (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).2
In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.
Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).
NIKTIMVO®, MINJUVI®, PEMAZYRE® and ZYNYZ® are trademarks of Incyte. All other trademarks are the property of their respective owners.
About cGVHD
Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor’s immune cells attack the recipient’s tissues, often occurring during the first-year post-transplant.3 Chronic GVHD involves features of autoimmunity and immunodeficiency, multiple organs (such as the skin, liver, lungs, and gastrointestinal tract), irreversible fibrotic manifestations, and systemic toxicities complicated by the use of immunosuppressants which all contribute to devastating health consequences such as mortality, morbidity, and decreased quality of life in patients.4 There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.5 Chronic GVHD is the most common late complication after allogeneic hematopoietic cell transplantation affecting 30%-70% of recipients, globally.4 Based on a recent analysis by the Brazilian National hematopoietic stem cell transplantation (HSCT) Registry, in collaboration with Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), Center for International Blood and Marrow Transplant Research (CIBMTR), and Hematopoietic Cell Transplantation Brazilian Registry (HCTBR), the 2-year cumulative incidence cGVHD was determined to be 29.5%.6
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's website at www.knighttx.com or www.sedarplus.ca.
Forward-Looking Statements for Knight
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.
References
ANVISA, Prescribing Information. Approved on October 5, 2026.Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Highlights of prescribing information / full prescribing information. Revised August 2024. Accessed June 10, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdfJagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215. doi:10.1016/j.bbmt.2007.07.001Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023;41(10):1864-1875. doi:10.1200/JCO.22.00958Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileiro de Transplantes (RBT): Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/setembro 2024 (Ano XXV, nº 3) [Report]. Retrieved May 26, 2026, from https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdfSimione, Anderson Joao, et al. “Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators.” Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT), vol. 6, no. 1, 2025, pp. 1–13. doi: 10.46765/2675-374X.2025V6N1P270. CONTACT INFORMATION FOR KNIGHT:
Společnosti Enterprise Products Partners a Energy Transfer nabízejí forwardový výnos 6,19 %, respektive 6,64 %; investice ve výši 100 000 USD rozdělená mezi obě společnosti by při současné výši distribucí přinesla ročně 6 413,47 USD.
Two midstream partnerships just got cheaper while their payouts stayed the same, pushing their yields above 6% and opening a window that income investors rarely see without taking on serious commodity risk.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Energy pays some of the highest yields in the market, and it carries a risk most income sectors avoid: commodity prices. When crude falls, an integrated major can lean on its refining business. A pure producer sees its cash flow rise and fall with oil and gas prices. A midstream operator collects fees on the volumes moving through its pipelines, plants and export docks, so its cash flow holds up better in a downturn.
Both names below are midstream partnerships. Over the past month, one fell 8.05% and the other fell 4.87%, while their distributions stayed the same. As a result, both forward yields are now above 6%. A $50,000 stake in each of these two ultra-high-yield names would generate the following. The total investment is $100,000, and it would produce more than $6,000 of passive income each year. Each yield is the latest quarterly distribution annualized.
Enterprise Products Partners Yield: 6.19% (forward, on a $2.24 annualized distribution and a $36.19 unit price) Units for $50,000: 1,381.6 Annual Passive Income: ~$3,094.78 Enterprise Products Partners (NYSE:EPD | EPD Price Prediction) runs an integrated North American midstream network that handles NGLs, crude oil, natural gas, petrochemicals and refined products. As an MLP, it passes nearly all of its available cash to unitholders, and its fee-based contracts support a payout well above the broader market’s. Second-quarter 2026 pipeline volumes hit a record 14.7 million barrels per day of oil equivalent.
Dividend safety is Enterprise’s strongest point. In Q2 2026, distributable cash flow reached a record $2.3 billion. That covered the distribution 1.9x and left $1.1 billion for growth projects and buybacks. Net leverage is at the company’s 3.0 target, and 97% of its debt is fixed rate. Enterprise paid 44.5 cents every quarter of 2020, and its growth streak now extends 27 consecutive years.
The bull case rests on $6.5 billion of growth projects under construction. These include an LPG export expansion on the Houston Ship Channel that is due by the end of 2026. One concern is that the record quarter exaggerates the normal run rate. Management credited about $200 million of Q2 results to unusually strong global demand in April and May and said those price differences “have largely normalized.” Because Enterprise is an MLP, holding its units in an IRA can generate unrelated business taxable income (UBTI).
Energy Transfer Yield: 6.64% (forward, on a $1.36 annualized distribution and a $20.49 unit price) Units for $50,000: 2,440.2 Annual Passive Income: ~$3,318.69 Energy Transfer (NYSE:ET) runs a diversified U.S. midstream system. It moves and stores natural gas, collects and processes gas and ships NGLs, refined products and crude oil. Its high payout comes from the same MLP structure.
Coverage looks solid today. Q1 2026 distributable cash flow rose to $2.70 billion from $2.31 billion a year earlier. Q2 adjusted EBITDA climbed 31% to $5.07 billion, and management raised full-year guidance to $18.8 billion to $19.1 billion. The $0.34 Q2 distribution was the 19th consecutive quarterly increase.
The partnership’s record in the last downturn is its weak spot. In November 2020, Energy Transfer cut its quarterly payout to $0.1525 from $0.305 and kept it there through 2021. The key risk is that under stress, management protected the balance sheet first. The bull case is rising gas demand. The Hugh Brinson Pipeline is scaling toward 1.5 Bcf/d. New supply agreements will deliver about 900 MMcf/d to data centers run by Oracle (NYSE:ORCL), and the Transwestern Desert Southwest expansion was expanded to as much as 2.3 Bcf/d. The same UBTI issue applies to IRA holders.
How $100,000 Splits Across Both Partnerships Name Yield Annual Dividend Income Enterprise Products Partners 6.19% $3,094.78 Energy Transfer 6.64% $3,318.69 Total 6.41% $6,413.47 What Midstream Cash Flow Delivers Each Year Together, these two positions generate $6,413.47 in annual passive income from a $100,000 investment, producing a combined yield of 6.41%. Enterprise Products Partners adds $3,094.78, and Energy Transfer rounds out the group with $3,318.69.
Enterprise is the stronger income anchor of the pair. It has 1.9x coverage and a distribution that held steady through 2020. Energy Transfer offers the higher yield and the bigger growth pipeline, but its payout cut means its coverage should be checked every quarter (the warning signs that a fat yield is about to be trimmed are the whole subject of our free dividend trap guide). Fee-based midstream income depends more on volumes than on prices, and that steady quarterly cash flow tops the $6,000 target with room to spare.
Contact [email protected] for any questions or corrections.
Společnost Hamilton Lane zveřejní hospodářské výsledky za druhé čtvrtletí fiskálního roku 2027, které skončilo 30. září 2026, před otevřením trhu 3. listopadu 2026.
, /PRNewswire/ -- Hamilton Lane Incorporated (Nasdaq: HLNE) is scheduled to release financial results for the second fiscal quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/.
Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on November 3 to discuss the results for the second fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least 15 minutes prior to the start of the call. This feature will be in listen-only mode.
A replay of the webcast will be available approximately two hours after the live broadcast for a period of one year, and can be accessed in the same manner as the live webcast on the Hamilton Lane Shareholders website.
About Hamilton Lane
Hamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 800 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has $1.1 trillion in assets under management and supervision, composed of more than $146 billion in discretionary assets and $914 billion in non-discretionary assets, as of June 30, 2026. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit our website or follow Hamilton Lane on LinkedIn.
MassMutual Private Wealth & Trust FSB grew its stake in shares of KLA Corporation (NASDAQ:KLAC – Free Report) by 62.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,958 shares of the semiconductor company’s stock after acquiring an additional 4,203 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in KLA were worth $2,136,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. McIlrath & Eck LLC lifted its holdings in shares of KLA by 6.8% during the 1st quarter. McIlrath & Eck LLC now owns 94 shares of the semiconductor company’s stock valued at $139,000 after buying an additional 6 shares during the period. SouthState Bank Corp grew its holdings in shares of KLA by 6.7% in the fourth quarter. SouthState Bank Corp now owns 111 shares of the semiconductor company’s stock worth $135,000 after acquiring an additional 7 shares during the period. Nemes Rush Group LLC grew its holdings in shares of KLA by 17.1% in the fourth quarter. Nemes Rush Group LLC now owns 48 shares of the semiconductor company’s stock worth $58,000 after acquiring an additional 7 shares during the period. Cornerstone Planning Group LLC increased its position in KLA by 36.4% during the first quarter. Cornerstone Planning Group LLC now owns 60 shares of the semiconductor company’s stock valued at $88,000 after acquiring an additional 16 shares during the last quarter. Finally, Stiles Financial Services Inc increased its position in KLA by 1.0% during the first quarter. Stiles Financial Services Inc now owns 1,783 shares of the semiconductor company’s stock valued at $2,625,000 after acquiring an additional 17 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors.
Insider Activity at KLA In related news, CEO Richard P. Wallace sold 72,019 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $171.88, for a total transaction of $12,378,625.72. Following the completion of the transaction, the chief executive officer owned 706,925 shares in the company, valued at approximately $121,506,269. This represents a 9.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brian Lorig sold 59,586 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $208.13, for a total transaction of $12,401,634.18. Following the transaction, the executive vice president directly owned 77,681 shares of the company’s stock, valued at $16,167,746.53. The trade was a 43.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 243,339 shares of company stock valued at $46,903,454. Corporate insiders own 79.39% of the company’s stock.
Analysts Set New Price Targets Several research analysts have issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $253.00 target price on shares of KLA in a research report on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating and set a $225.00 price target on shares of KLA in a research report on Monday, July 20th. Needham & Company LLC reissued a “buy” rating and issued a $270.00 price objective on shares of KLA in a report on Wednesday, July 29th. TD Cowen restated a “buy” rating and set a $260.00 target price (up from $200.00) on shares of KLA in a research report on Thursday, July 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of KLA in a report on Wednesday, June 17th. Eighteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, KLA presently has a consensus rating of “Moderate Buy” and a consensus price target of $222.22. Read Our Latest Report on KLAC
KLA Stock Down 0.0% Shares of KLAC stock opened at $206.85 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.88 and a quick ratio of 2.03. KLA Corporation has a one year low of $98.10 and a one year high of $307.37. The company’s fifty day moving average price is $186.79 and its 200-day moving average price is $194.65. The company has a market capitalization of $269.94 billion, a price-to-earnings ratio of 56.41, a PEG ratio of 1.84 and a beta of 1.45.
KLA (NASDAQ:KLAC – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The semiconductor company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.05. The business had revenue of $3.66 billion during the quarter, compared to analyst estimates of $3.61 billion. KLA had a return on equity of 87.66% and a net margin of 35.57%.KLA’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.94 EPS. KLA has set its Q1 2027 guidance at 1.060-1.260 EPS. Sell-side analysts expect that KLA Corporation will post 5.41 EPS for the current fiscal year.
KLA Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Monday, August 17th were paid a $0.23 dividend. This represents a $0.92 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, August 17th. This is a positive change from KLA’s previous quarterly dividend of $0.23. KLA’s dividend payout ratio is currently 25.07%.
About KLA (Free Report)
KLA Corporation (NASDAQ: KLAC) develops process-control and yield-management solutions used by semiconductor and electronics manufacturers. Its systems help customers detect defects, measure and analyze materials and structures, and monitor manufacturing processes throughout the production of integrated circuits and other advanced electronic components.
The company’s product portfolio includes inspection and metrology systems, wafer and reticle inspection equipment, process-control software, data analytics tools, and related services.
Further Reading Five stocks we like better than KLA NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for KLA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KLA and related companies with MarketBeat.com's FREE daily email newsletter.
CHANTILLY, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) will release third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The company will host a conference call at 8:00 a.m. Eastern Time that day to discuss its earnings results and guidance, followed by a question-and-answer session.
Access to a webcast of the live conference call can be obtained through the Investor Relations section of the company's website (https://investors.parsons.com). Those parties interested in participating via telephone may register on the Investor Relations website or by clicking here.
A replay will be available on the company's website approximately two hours after the conference call and continuing for one year.
About Parsons Corporation
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.
Contacts:
Media
Bernadette Miller
Parsons Corporation
+1 980.253.9781 [email protected]
Investor Relations
Dave Spille
Parsons Corporation
+1 571.775.0408 [email protected]
Akcie společnosti SoundHound AI letos klesly o 41,6 %, přesto firma po akvizici společnosti LivePerson očekává, že její tržby v roce 2027 dosáhnou 350 až 400 mil. USD.
Artificial intelligence (AI) audio agent company SoundHound AI (SOUN +0.69%) has disappointed shareholders thus far in 2026. As of this writing, the stock is down 41.6%, while the S&P 500 has climbed 12.8% over the same period.
Based on analyst forecasts, 2027 could offer a better performance, but even with those forecasts, a note of caution is warranted.
Image source: The Motley Fool.
The stock price forecast Overall, based on analyst price targets, there could be significant upside for SoundHound stock by October 2027. The stock doesn't receive much coverage, but among the eight analysts tracking it, the median one-year price target is $13.50, according to CNN. From the Oct. 2 closing price of $5.84, that would be a gain of 131%.
The most bullish target, $17, would represent a 191% gain, and even the lowest target, $7, is a nearly 20% gain.
However, that is still based on a small group of analysts, and price targets aren't guarantees; they essentially offer sentiment around an investment more than anything else. In addition, based on the risks, those targets seem a bit optimistic, even a year out.
The upside and risks SoundHound is an intriguing investment, but it comes with plenty of uncertainty. On the one hand, it has managed to line up an impressive list of clients, from the car manufacturer Stellantis to the restaurant chain Five Guys, giving it an early lead in the audio AI agent space. And after it closed the acquisition of LivePerson in September, SoundHound could become an even more robust platform. Whereas SoundHound's specialty is in the audio space, LivePerson's is messaging, with its AI agents handling tasks like automated texts or email replies for a business.
At the time of the acquisition announcement in April, SoundHound expected its 2027 revenue totals to fall within a range of $350 million to $400 million, with $100 million of growth from sales contributions from LivePerson's customers. For context, SoundHound's 2025 full-year revenue was $168.9 million, so the climb up to as much as $400 million so soon is promising.
Premium Feature
Moneyball Superscore
69/100
Today's Change
(
0.69
%) $
0.04
Current Price
$
5.88
That said, the risks remain significant. Regarding the LivePerson deal, one risk is that the synergies SoundHound expects will take longer than anticipated to materialize or may not materialize at all. Also, the AI agent space is becoming increasingly competitive. Hence, an additional threat is that a much larger company with a bigger bankroll, such as Alphabet, Amazon, or Microsoft, could start encroaching on SoundHound's market. Even the start-ups OpenAI and Anthropic could broadly be considered indirect competitors with their AI agents.
With all that in mind, I still view SoundHound as worthy of a small, speculative position in a portfolio. But making meaningful wealth from the stock will take more time. SoundHound has to execute on integrating LivePerson and demonstrate the expected revenue growth and operational efficiencies the merger created, or, better yet, exceed expectations. For the short term, I don't see too many catalysts that would send the stock price higher.
That's why I would also be comfortable sitting on the sidelines and not buying it or adding to a position. If it starts to move higher on company-specific news over the next year, that at least shows it has renewed momentum. And if it heads lower, that may provide a more favorable entry point for long-term investors.
Applied Digital získala ve Finsku přístup k potenciální kapacitě dodávek elektřiny až 1 GW pro kampus datového centra pro AI, přičemž první dodávky elektřiny se očekávají od roku 2028.
DALLAS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a U.S. based designer, developer, owner and operator of large-scale, purpose-built data centers to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”), machine learning, and other accelerated-compute applications, today announced it has entered into an agreement providing access to up to 1 gigawatt (GW) of potential power capacity in Finland, representing the Company’s first development opportunity outside of the United States.
With this agreement, the Company plans to build a large-scale AI Factory campus capable of scaling to as much as 1 GW. Initial power availability is anticipated beginning in 2028. Applied Digital has begun marketing the site and is currently engaged in discussions with leading global hyperscale customers.
While Applied Digital’s near-term development strategy and execution priorities remain firmly centered on its growing U.S. portfolio, Finland represents a measured first step toward selectively extending the Company’s platform into attractive international markets over time. The agreement was structured to provide meaningful long-term growth potential while limiting the Company’s initial exposure and maintaining disciplined capital deployment.
“Applied Digital has built its platform around identifying the right power in the right markets and turning that power into operational AI capacity,” said Wes Cummins, Chairman and CEO of Applied Digital. “Finland stood out because many of the characteristics that have supported our success in North Dakota are also present in the Nordics — a favorable climate, an attractive energy ecosystem, strong connectivity and the ability to develop at meaningful scale.”
Cummins continued, “This is a deliberate first step, not a change in our strategy. Our focus remains firmly on executing the projects in front of us in the United States. At the same time, as we continue building Applied Digital into a category leader in AI infrastructure, we believe it is important to selectively secure compelling sites that can extend our growth runway over the long term.”
Finland has emerged as an increasingly attractive market for hyperscale and AI development, supported by its cooler climate, established energy and digital networks, and growing investment from global technology leaders. Applied Digital believes these characteristics align closely with the development principles that underpin its U.S. portfolio: securing scalable power and land in markets where AI capacity can be developed efficiently, responsibly and repeatedly.
The Finland campus represents the first potential application of Applied Digital’s AI Factory campus development model outside the U.S. The Company intends to advance the project in a disciplined manner, with future investment and development decisions tied to customer demand, commercial milestones and the achievement of necessary regulatory and development requirements.
“Our ability to scale is not about planting flags in as many markets as possible,” Cummins said. “It is about identifying exceptional sites and applying the same disciplined model repeatedly. We have demonstrated that model across our U.S. portfolio. Finland gives us the opportunity to begin proving that platform can travel.”
About Applied Digital
Applied Digital (Nasdaq: APLD) — named Best Data Center in the Americas 2025 by Datacloud — designs, builds, and operates high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads. Headquartered in Dallas, TX, and founded in 2021, the company combines hyperscale expertise, closed-loop cooling, and rapid deployment capabilities to deliver secure, scalable compute at industry-leading speed and efficiency, while creating economic opportunities in underserved communities through its AI Factory franchise model.
Learn more at applieddigital.com or follow @APLDdigital on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives, and future financing plans. These statements use words, and variations of words, such as “will,” “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “proven,” “deliver,” “outlook,” “expect,” “project” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements that reflect perspectives and expectations regarding lease agreements and any current or prospective data center campus development; (ii) statements about the high-performance computing (HPC) industry; (iii) statements of company plans and objectives, including the company’s evolving business model, or estimates or predictions of actions by suppliers; (iv) statements of future economic performance; (v) statements regarding international markets and expansion and development internationally, and (vi) statements of assumptions underlying other statements and statements about the company or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the company’s expectations and projections. These risks, uncertainties, and other factors include, among others: whether or not our customers exercise the renewal options under their leases with us (if not, we will not recognize further revenue from such customer under its respective lease); our ability to complete construction of our data center campuses as planned, including internationally; the lead time of customer acquisition and leasing decisions and related internal approval processes; changes to artificial intelligence and HPC infrastructure needs and their impact on future plans; costs related to the HPC operations and strategy; our ability to timely deliver any services required in connection with completion of installation under lease agreements; our ability to raise additional capital to fund the ongoing datacenter construction and operations; differences in sourcing materials and labor internationally; our ability to obtain financing of datacenter leases and more broadly for our development and general corporate activities; our dependence on principal customers, including our ability to execute and perform our obligations under our leases with key customers; our ability to timely and successfully build new hosting facilities with the appropriate contractual margins and efficiencies; power or other supply disruptions and equipment failures; the inability to comply with regulations, developments and changes in regulations, including internationally; cash flow and access to capital; availability of financing to continue to grow our business; decline in demand for our products and services; maintenance of third party relationships; and conditions in the debt and equity capital markets. A further list and description of these risks, uncertainties, and other factors can be found in the company’s most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, including in the sections captioned “Forward-Looking Statements” and “Risk Factors,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, on the company’s website (www.applieddigital.com) under “Investors,” or on request from the company. Information in this press release is as of the dates and time periods indicated herein, and the company does not undertake to update any of the information contained in these materials, except as required by law.
Universal Corporation (NYSE:UVV – Get Free Report)’s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $50.48 and traded as low as $41.54. Universal shares last traded at $42.2690, with a volume of 355,699 shares changing hands.
Analyst Ratings Changes Several equities analysts have recently weighed in on UVV shares. Weiss Ratings downgraded shares of Universal from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Zacks Research lowered shares of Universal from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Finally, Wall Street Zen raised shares of Universal from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Universal has an average rating of “Reduce”.
View Our Latest Report on UVV
Universal Stock Up 0.2% The company has a market cap of $1.05 billion, a PE ratio of 54.90, a P/E/G ratio of 13.27 and a beta of 0.58. The stock has a 50-day moving average of $46.04 and a 200-day moving average of $50.48. The company has a quick ratio of 1.00, a current ratio of 2.57 and a debt-to-equity ratio of 0.43. Universal (NYSE:UVV – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.43). Universal had a return on equity of 3.50% and a net margin of 0.67%.The business had revenue of $523.78 million during the quarter, compared to the consensus estimate of $587.00 million. Sell-side analysts predict that Universal Corporation will post 3.18 earnings per share for the current fiscal year.
Universal Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Monday, October 12th will be issued a $0.83 dividend. This represents a $3.32 dividend on an annualized basis and a dividend yield of 7.9%. The ex-dividend date is Friday, October 9th. Universal’s dividend payout ratio is presently 431.17%.
Insider Transactions at Universal In other news, Director Lennart Freeman sold 1,782 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $49.82, for a total value of $88,779.24. Following the completion of the sale, the director directly owned 16,935 shares in the company, valued at approximately $843,701.70. The trade was a 9.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Universal Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. boosted its position in shares of Universal by 67.1% in the 1st quarter. Bessemer Group Inc. now owns 518 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares in the last quarter. CoreCap Advisors LLC raised its stake in Universal by 2.7% in the second quarter. CoreCap Advisors LLC now owns 23,641 shares of the company’s stock valued at $1,233,000 after buying an additional 630 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Universal in the fourth quarter worth about $47,000. GAMMA Investing LLC boosted its holdings in Universal by 30.9% in the second quarter. GAMMA Investing LLC now owns 3,980 shares of the company’s stock worth $208,000 after acquiring an additional 940 shares in the last quarter. Finally, Pzena Investment Management LLC grew its stake in shares of Universal by 0.6% during the first quarter. Pzena Investment Management LLC now owns 329,488 shares of the company’s stock worth $17,364,000 after acquiring an additional 1,810 shares during the last quarter. 81.00% of the stock is currently owned by institutional investors.
About Universal (Get Free Report)
Universal Corporation (NYSE: UVV) is a global leaf tobacco supplier and processor. Through its operating companies, the company purchases tobacco from growers, processes and blends leaf, and supplies tobacco products and related materials to manufacturers of cigarettes, cigars, pipe tobacco and other tobacco products. Its services include crop contracting, agricultural support, curing, processing, storage, packaging and logistics.
Founded in 1918 and headquartered in Richmond, Virginia, Universal has developed an international network of tobacco sourcing, processing and distribution operations.
Recommended Stories Five stocks we like better than Universal NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Receive News & Ratings for Universal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universal and related companies with MarketBeat.com's FREE daily email newsletter.
